
Title:  Randomized, Double-Blind, Placebo-Controlled, Three-Part Phase 1 Study to Evaluate the 
Safety, Tolerability, and Pharmacokinetics of TAK-951 in Healthy Subjects
Study ID: [REMOVED]
Protocol Approve Date: 23 September 2020
Certain information within this protocol has been  redacted (ie, specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiab le information (PPD) or company 
confidential information (CCI). 
This may includ
e, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
TAKEDA PHARMACEUTICALS
PROTOCOL
A Rando mized, Double -Blind, Pl acebo -Controlled, Three -Part Phase 1 Study  to Eval uate the 
Safety, Tolerabili ty, and Pharmacokinet ics of TAK -951 in Healt hy Subjects
Study Identifier: TAK-951-1001
Compound: TAK-951
Date: 23 September 2020
Amendment 
Number:4.0
Amendment History :
Date Amendment Number Amendment Type All Sites
03 January 2019 Initial protocol Not applicable United States
11 April 2019 01 Substantial United States
15 May  2019 02 Substantial United States
28June 2019 03 Substantial United States
23 September 2020 04 Substantial United States
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 2of 91
Protocol Incorporating Amendment No. 04 23 September 2020
TABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 7
1.1 Protocol  Amendment 04 Summary  of Changes ........................................................ 10
2.0 STUDY SCHEMATIC .................................................................................................. 11
3.0 SCHEDULE OF STUDY PR OCEDURES .................................................................... 12
3.1 Part 1 for SRD Cohorts 1 to 6 and 13 to 19 .............................................................. 12
3.2 Part 2 has been removed from  the study  in Protocol Amendment 04 ........................ 14
3.3 Part 3 for MRD Cohorts 10 to 12 and 20: Days 1 Through 5 and Early Terminat ion
15
3.3.1 Part 3 Day  1 Assessments ................................................................................ 18
3.3.2 Part 3 Day s 2 to 4 Assessments ........................................................................ 22
3.3.3 Part 3 Day  5 Assessments and Early  Terminat ion............................................ 24
4.0 INTRODUCTION ......................................................................................................... 26
4.1 Background ............................................................................................................. 26
4.2 Rationale for the Proposed Study ............................................................................. 26
4.3 Benefit -Risk Profile .................................................................................................26
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 27
5.1 Study  Objectives ...................................................................................................... 27
5.1.1 Study  Primary  Object ive.................................................................................. 27
5.1.2 Study  Secondary  Object ive.............................................................................. 27
5.1.3 Study  Expl oratory  Object ives.......................................................................... 27
5.2 Endpoints ................................................................................................................. 28
5.2.1 Primary Endpo int............................................................................................. 28
5.2.2 Secondary  Endpo ints....................................................................................... 28
5.2.3 Exploratory  Endpo ints..................................................................................... 28
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 29
6.1 Study  Design ........................................................................................................... 29
6.1.1 Part 1: SRD Cohorts 1 to 6 and 13 to 19 ........................................................... 30
6.1.2 Part 2 ............................................................................................................... 31
6.1.3 Part 3: MRD Cohorts 10 to 12 and 20 .............................................................. 31
6.2 Rationale for Study  Design, Dose, and Endpoints .................................................... 32
6.2.1 Rationale of Study  Design ............................................................................... 32
6.2.2 Rationale for Dose ........................................................................................... 33
6.2.3 Starti ng Dose for This Study ............................................................................ 35
6.2.4 Rationale for Endpoints ................................................................................... 35
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 3of 91
Protocol Incorporating Amendment No. 04 23 September 2020
6.2.5 Critical Procedures Based on Study  Object ives: Timing of Procedures ............ 36
6.3 Study  Design/Dosing/Procedures Modificat ions Permitted Within Protocol 
Param eters ............................................................................................................... 36
6.4 Study  Beginning and End/Co mpletion..................................................................... 37
6.4.1 Definit ion of Beginning o f the Study ............................................................... 37
6.4.2 Definit ion of End of the Study ......................................................................... 37
6.4.3 Definit ion of Study  Discont inuat ion.................................................................37
6.4.4 Criteria for Premature Terminat ion or Suspension of a Site .............................. 38
6.4.5 Stopping Rules ................................................................................................ 38
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 39
7.1 Inclusio n Cri teria..................................................................................................... 39
7.2 Exclusio n Cri teria.................................................................................................... 40
7.3 Excluded/Allowed Conco mitant Medi cations, Supplements, Dietary  Products ......... 41
7.3.1 Concomitant Medications ................................................................................ 41
7.3.2 Fruit Juice........................................................................................................ 42
7.3.3 Alcoho l............................................................................................................ 42
7.3.4 Caffeine ........................................................................................................... 42
7.3.5 Smoking .......................................................................................................... 42
7.4 Diet, Fl uid,Activity.................................................................................................42
7.4.1 Diet and Fluid .................................................................................................. 42
7.4.2 Activity........................................................................................................... 43
7.5 Criteria for Di scontinuati on or Wi thdrawal  of a Subject ........................................... 43
7.6 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 44
7.7 Subject Replacement ................................................................................................ 44
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 44
8.1 Clinical Study  Drug .................................................................................................44
8.1.1 Study Drugs ..................................................................................................... 44
8.1.2 Clinical Study  Drug Labeling .......................................................................... 44
8.1.3 Clinical Study  Drug Inventory  and Storage ...................................................... 45
8.1.4 Clinical Study  Drug Blinding ........................................................................... 45
8.1.5 Randomization Code Creation and Storage ...................................................... 45
8.1.6 Clinical Study  Blind Maintenance/Unblinding Procedure .................................45
8.1.7 Accountabilit y and Destruction of Sponsor -Supplied Drugs ............................. 45
8.2 Ancillary  Supplies ................................................................................................... 46
9.0 STUDY PROCEDURES ............................................................................................... 46
9.1 Administ rative Procedures ....................................................................................... 47
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 4 of 91Protocol Incorporating Amendment No. 04 23 September 2020
9.1.1 Informed Consent Procedure ............................................................................47
9.1.2 Inclusion and Exclusion...................................................................................47
9.1.3 Medical History /Demography..........................................................................47
9.2 Clinical Procedures and Assessments .......................................................................47
9.2.1 Full P hysical Examination ...............................................................................47
9.2.2 Height a nd Weight ...........................................................................................48
9.2.3 Body Mass Index .............................................................................................48
9.2.4 Vital Signs.......................................................................................................48
9.2.5 Glucose ...........................................................................................................48
9.2.6 ECG Proce dure................................................................................................49
9.2.7 Study Drug Administration ..............................................................................50
9.2.8 ........................................................................50
9.2.9 AE Monit oring ................................................................................................50
9.3 Laboratory Procedure s and Assess ments ..................................................................50
9.3.1 Hematol ogy.....................................................................................................50
9.3.2 Chemistry ........................................................................................................51
9.3.3 Urinalysi s ........................................................................................................51
9.3.4 Diagnostic Scr eening .......................................................................................51
9.4 PK,  and Immunogenicity Samples ..........................52
9.4.1 PK Measur ements ............................................................................................53
9.4.2 Immunogenicity (A DA) Measur ements ...........................................................55
9.4.3 ................................................................................55
9.4.4 ...................................................................56
9.5 Confinement ............................................................................................................57
9.5.1 Part 1 (S RD)....................................................................................................57
9.5.2 Part 2 (SD Apo Challenge) ..............................................................................57
9.5.3 Part 3 (M RD)...................................................................................................58
9.6 Childbearing Status and Methods of Cont raceptio n..................................................58
9.6.1 Women of Childb earing Poten tial....................................................................58
9.6.2 Women of Nonchil dbearing Po tential ..............................................................58
10.0 ADVERSE EVEN TS ....................................................................................................58
10.1 Definitions and El ements of AE s .............................................................................58
10.1.1 SAEs ...............................................................................................................60
10.1.2 Special Interes t AEs.........................................................................................61
10.2 AE Proce dures .........................................................................................................62CCI
CCI
CCICCI
Property of Takeda: For Non-Centent.....
Part 1 (Sart 1 (
Part 2Part
3 PaP
ChiCCommercial.............
yy(A(AyyDADUse Only and Subject to the Applicable Terms of Use477
.......4747
..............
...............
............
................
...............
.............
...............
...........
...............
................
.............
.............
............
...............
9.6.9.6
10.010.0Comm-Coal Us
TAK-951
Study ID TAK-951-1001 Page 5 of 91Protocol Incorporating Amendment No. 04 23 September 2020
10.2.1 Assigning Severity of AEs ...............................................................................62
10.2.2 Assi gning Causality of AEs .............................................................................62
10.2.3 Start D ate.........................................................................................................62
10.2.4 End Date ..........................................................................................................62
10.2.5 Pattern of AE (F requency) ...............................................................................63
10.2.6 Action Taken With Study Treatm ent................................................................63
10.2.7 Outcome ..........................................................................................................63
10.2.8 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal 
LFTs................................................................................................................63
10.2.9 Safety Reporting to Investigators, IRBs, and Regulatory Authorities ................66
11.0 STATISTICAL METHODS ..........................................................................................66
11.1 Statistical and Analytical Plans ................................................................................66
11.1.1 Analysis S ets ...................................................................................................67
11.1.2 Analysis of Demography and Ot her Baseline Cha racteristi cs ...........................67
11.1.3 .......................................................67
11.1.4 PK Analysi s.....................................................................................................67
11.1.5 Safety Analy sis................................................................................................68
11.1.6 ....................................................................................68
11.1.7 Immunoge nicity Analysis ................................................................................68
11.2 Interim Analysis and Criteria for Early Termination ................................................69
11.3 Determination of Sample Size ..................................................................................69
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ...............................................69
12.1 Study-Site Monito ring Visits ...................................................................................69
12.2 Protocol Devi ations..................................................................................................69
12.3 Qu ality Assurance A udits and Regu latory Agency Inspections ................................69
13.0 ETHICAL ASPECTS OF THE STUDY ........................................................................70
13.1 IRB Approva l ..........................................................................................................70
13.2 Subject Information, Informed Consen t, and Subject Authorization .........................71
13.3 Subject Confidentiality ............................................................................................72
13.4 Publication, Disclosure, and Clinical Study Registration Policy ...............................72
13.4.1 Pub lication and Disclosure ...............................................................................72
13.4.2 Clinical Trial Regi stration ................................................................................73
13.4.3 Clinical Study Result s Disclos ure ....................................................................73
13.5 Insurance and Compensation for Injury ....................................................................73
14.0 ADMINISTRATIVE AND REFERENCE INFORMATION .........................................74
14.1 Administrative Information ......................................................................................74CCI
CCI
Property of Takeda: For Non-Commercial Use Only an.............
................
............
ysissis......
iteria foeria fo
mple Sizple S
OL ANDL AN
ninitoringtoriiii
eviatviatio
yAssuraAssu
AL ASPAL AS
IRB ApRB A
SubjSubnd Subject to the Applicable Terms of Use622
.......6262
..............
...............
............
s, and Aand 
...............
ryryAuthAuthyy
.............
.............
..............
eline Chine C
3.33.3 S
13.413and S
TAK -951
Study ID TAK -951-1001 Page 6of 91
Protocol Incorporating Amendment No. 04 23 September 2020
14.1.1 Study  Contact Informat ion............................................................................... 74
14.1.2 INVESTIGATOR AGREEMENT ................................................................... 75
14.1.3 Study -Related Responsibilit ies......................................................................... 76
14.1.4 List of Abbreviat ions....................................................................................... 77
15.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 79
15.1 CRFs (El ectronic and Paper) .................................................................................... 79
15.2 Record Retention ..................................................................................................... 79
16.0 REFERENCES .............................................................................................................. 80
17.0 APPENDICES ............................................................................................................... 81
LIST OF IN -TEXT TABLES
Table 6.a Overview of Treatment Cohorts ......................................................................... 30
Table 6.b Predi cted Hum an Dose -Related Concentrations and Exposures for Planned 
Doses in Part 1 ................................................................................................... 35
Table 9.a Primary Specimen Collections ........................................................................... 53
Table 10.a Takeda Medically Significant AE List ................................................................ 61
Table 10.b NCI CTCAE ...................................................................................................... 62
LIST OF APPENDICES
Appendix AResponsibilit ies o f the Invest igator ..................................................................... 81
Appendix B Elements of the Subject Informed Consent ......................................................... 83
Appendix C Invest igator Consent to the Use of Personal Information .................................... 86
Appendix D Pregnancy and Contraception ............................................................................. 87
Appendix E Detailed Descript ion of Amendments to Text ..................................................... 90
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 7 of 91Protocol Incorporating Amendment No. 04 23 September 2020
1.0 STUDY SUMMARY
Name of Sponsor:
Millennium Pharmaceuticals, Inc. (Takeda Global Research and 
Development –United States)Compound:
TAK-951
Study Identifier : TAK-951-1001 Phase: 1
Protocol Title: A Randomized, Double-Blind, Placebo-Controlled, Three-Part Phase 1 Study to Evaluate the Safety, 
Tolerability, and Pharmacokinetics of TAK-951 in Healthy Subjects.
Study Design:
This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and 
pharmacokinetics (PK) of TAK-951 in healthy subjects. 
The study will consist of 2 parts: 
!Part 1 is a first-in-human (FIH), randomized, double-b lind, placebo-controlled, singl e-rising dose (SRD) study to
assess the safety, tolerability, and PK of TAK-951 in healthy volunteers. Up to 13 cohorts may be enrolled.
Subjects will be randomized to receive TAK-951 or matching placebo.
!Part 2 of the study has been removed in Protocol Amendment 04 dated 23 September 2020
!Part 3 is a randomized, double-blind, placebo-controlled, multiple-rising dose (MRD) study. 
Safety and tolerability will be assessed during all parts of the study through physical examination, including vital sign 
assessment, electrocardiogram (ECG)/telemetry, clinical laboratory assessments, collection of adverse events (AEs) 
and immunogenicity.
TAK-951 and matching placebo will be administered subcutaneously. 
Study Primary Objective:
!Part 1
– To characterize the safety (including immunogenicity) and tolerability of single subcutaneous (SC) doses of
TAK-951 in healthy subjects.
!Part 3
– To characterize the safety (including immunogenicity) and tolerability of multiple SC doses of TAK-951 in
healthy subjects.
Study Secondary Objective
!Part 1
– To characterize the PK of TAK-951 following single SC doses in healthy subjects.
!Part 3
– To characterize the PK of TAK-951 following multiple SC doses in healthy subjects.
Study Exploratory Objectives
CCICCICCI
Property of Takeda: For Non-Commercial Uncludingcludin
ects.cts.
he safety safe
ts.s.
ObjectiveObjectiv
haracteraracte
3
To chTo 
tudy Expdy El Use Only the studyhe stud
al laboralabo
tered subered sulU
pepeerty oCCICCand Subject to the Applicable Terms of Useofof
er
luate the uate tT
y, toleraby, toler
ed, singled, sing
Up to 13Up to 
dated ted 2323
ultipleltiple -rica
ya n
TAK-951
Study ID TAK-951-1001 Page 8 of 91Protocol Incorporating Amendment No. 04 23 September 2020
Study Subject Population: Healthy volunteers aged 18 to 55 years, inclusive.
Planned Number of Subjects:
Part 1: up to 104
Part 2: Has been removed from the study in Protocol Amendment 04.Part 3: up to 32Planned Number of Sites:
This study is planned on being conducted at one or more 
sites within the United States. 
Dose Levels:
Part 1: TAK-951 SRD: starting dose 20 μg.
Part 2: has been removed from the study in Protocol Amendment 04.
Part 3: TAK-951 MRD: dose to be confirmed based on 
SRD results.Route of Administration:
TAK-951
Duration of Treatment:
Part 1: 1 day.
Part 2: Has been removed from the study in Protocol Amendment 04.Part 3: 5 days.Planned Study Duration:
Total approximately up to 155 days.
Part 1: screening, 28 days; treatment period, 1 day; follow-up, 14-32 days. Part 2: Has been removed from the study in Protocol Amendment 04.Part 3: screening, 28 days; treatment period, 5 days; follow-up, 14-32 days.
Main Criteria for Inclusion:
To be eligible for study participation, subjects must: 1. Understand the study procedures and agree to participate by providing written informed consent.
2. Be willing and able to comply with all study procedures and restrictions.
3. Be a healthy male or WONCBP (woman of nonchildbearing potential) female subject aged 18 to 55 years, 
inclusive, at the screening visit.
4. Have a BMI ≥18 and ≤30.0 (kg/m
2) at the screening visit.
5. Be judged to be in good health by the investigator, based on clinical evaluations including laboratory safety tests, 
medical history, physical examination, ECG, and vital sign measurements performed at the screening visit and before administration of the initial dose of study drug or invasive procedure.
Main Criteria for Exclusion:
The subject must be excluded from participating in the study if: 
1. The subject has participated in anothe r investigational study within 4 weeks (or based on local regulations) before 
the screening visit. The 4-week window will be de rived from the date of the last study procedure and/or AE 
related to the study procedure in the previous st udy to the screening vi sit of the current study.
2. The subject is an employee of the sponsor or study site or immediate family member (eg, spouse, parent, child, 
sibling) of the sponsor or study site.
3. The subject has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy) or has had an 
anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
4. The subject has a known hypersensitivity or contraindication to any component of TAK-951. 
5. The subject has a positive pregnancy test. Women of childbearing potential are not eligible for the study.
6. The subject is a lactating/nursing woman.
7. The subject has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, CCI
or ExcluExcl
must be eust be
subject haubject h
e screenie scree
related trelate
2.The Th
si
3.3For Non-Commercial Use Only and Subject to the Applicable Terms of Usefffffofof
or more or moresooooo
ca
urationration
mately ately up
ening, 28ning, 2
p, 14, 14-32 3
 HHas beeas b
mendmenndme
Part 3: scart 3: 
followfolltt
eO
must: must: 
gree to pree to 
all studyll stud
(woman(wom
sit.t.
.0 (kg/m(kg/m2
od healthod heal
hysical exysical e
ration of tion oeOeOeO
Fo
pepe
TAK -951
Study ID TAK -951-1001 Page 9of 91
Protocol Incorporating Amendment No. 04 23 September 2020
orHIV antibody/antigen, at thescreening visit. Note: Subjects with positive hepatitis B virus orhepatitis C 
virus serology may be enrolled if quantitative reverse transcriptase -poly merase chain reaction forhepatitis B 
virus orhepatitis C virus RNA is negative.
8.The subject had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks before 
the screening visit.
9.The subject is unable to refrain from or an ticipates using all medications, including herbal medicines, beginning 
approximately 7 days before administration of the first dose of study drug throughout the study until 2 days after 
discharge. 
Main Criteria for Evaluation and Analyses:
The primary endpoint of the study is safety and tolerability as assessed through physical examinations, vital signs, 
ECG/telemetry, laboratory assessments, AEs, and immunogenicity.
The secondary endpoints will be assessed through evaluation of the following PK paramet ers on Day 1 in Parts 1 and 
3, at steady state: 
Part 1: plasma PK parameters for TAK -951
–Maximum observed plasma concentration (C max)
–Area under the plasma concentration time curve from time 0 to infinity (AUC ∞)
Part 3: plasma PK parameters for TAK -951
– C maxon Day  1.
–Area under the plasma concentration -time curve during a dosing interval where tau (τ) is the length of the 
dosing interval (AUCτ) on Day 1.
Statistical Considerations:
The primary, secondary, and exploratory endpoints will be analyzed in rand omized subjects in Parts 1 and 3 who 
received at least 1 dose of study drug.
Safety analyses will be based on the safety analysis set. All safety data including AEs, vital signs, and ECG will be 
summarized using descriptive statistics. No formal statistica l tests or inference will be performed for safety analyses. 
All summaries will be performed by pooled placebo within each part and by TAK -951 dose level.
The PK parameters of TAK -951 will be summarized by dose, cohort, day, and dosing regimen (as appropriate), using 
descriptive statistics. Dose proportionality will be assessed graphically (dose -normalized C maxand AUC versus dose); 
no formal statistical comparisons will be conducted.
Sample Size Justification:
For Parts 1 and 3, the chosen sample sizes are considered sufficient for evaluation of safety, tolerability, and PK. The 
study is not statistically powered to perform hypothesis testing in Parts 1 and 3.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 10 of 91Protocol Incorporating Amendment No. 04 23 September 2020
1.1 Protocol Amendment 04 Summary of Changes
This document describes the changes in reference to the protocol incorporating amendment 04. 
The primary reason for this amendment is to remove all references to Part 2 of the study to
Minor grammatical, editorial, formatting, and administrative changes not affecting the conduct of 
the study are included for clarification and administrative purposes only.
For specific descriptions of text changes and where the changes are located, see Appendix E.
Changes in Amendment 04
1. Removed all references to Part 2 from the study.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee condue cond
eeAppeAppms o
TAK-951
Study ID TAK-951-1001 Page 11 of 91Protocol Incorporating Amendment No. 04 23 September 2020
2.0 STUDY SCHEMATIC
 intravenous; MRD: multiple-rising dose; SC: subcutaneous; SD: single dose; SRD: single-rising 
Refer to Table 6.a for a full overview of treatment cohorts, including planned treatments.
Part 2 of Study TAK-951-1001 has been removed from the study in Protocol Amendment 04.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useintravintra
e 6.a6.aforfo
Study TAStudy T
rNNNooooooooooooooooooon---CCCooommmmm
rcial Use Only aaannnnnnnnnnnnnnnnnnddddddddddddddddddddddddd SSSubjec
F
TAK -951
Study ID TAK -951-1001 Page 12of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIAL3.0 SCHEDULE OF STUDY PROCEDURES
3.1 Part 1 for SRD Cohorts 1 to 6 and 13 to 19
Day Scheduled Time
Early 
Termination-28 to -2 -1 Day 1 (Hours)
Follow -up Visit 
Day 14±2 daysFollow -up Visit 
Day 29 ±3 days ScreeningPre-
dose 00.5 1 2 3 4 6 8 10 12 14 16 2430
(discharge) 48 a
Administrative Procedures
Informed consent X
Inclusion/exclusion criteria X X X
Medical history/demographics X
Prior and concomitant medication 
reviewX X-------------------------------------------------------------------- Continuous Review----------------------------------------------------------------- X
Clinic Procedures/Assessments
Full physical examination X X X X
Height X
Weight and BMI X X
TAK -951/placebo administration bX
Temperature and respiratory rate X X X X X X
Blood pressure and pulse cX X X X X X X X X X X X X X X X X
Standing blood pressure and pulse dX X X X X X X
12-lead ECGs X X X X
Telemetry X------------------------- Continuous Monitoring ------------------------- X
Holter monitoring X X X X X X X X X X X X X X
AE monitoring XeX--------------------------------------------------------Continuous Monitoring ------------------------------------------------- X X
Laboratory Procedures/Assessments
Safety laboratory collection 
(hematology and serum chemistry)X X X X X X
Urinalysis X X X X
Glucose finger stick X X X
Urine drug screen X X
Alcohol breath test X
Cotinine test X X
Hepatitis screen fX
HIV screen X
βhCG (pregnancy) test gX X X X
Serum FSH test hX
PK Evaluations
Blood sample for PK X X X X X X X X X X X X X X X X
Urine sample for PK iX X X X X X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 13 of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIALDay Scheduled Time
Early 
Termination-28 to -2 -1 Day 1 (Hours)
Follow-up Visit 
Day 14±2 daysFollow-up Visit 
Day 29 ±3 days ScreeningPre-
dose 0 0.5 1 2 3 4 6 8 10 12 14 16 2430
(discharge) 48 a
Biomarker Evaluations
Blood sample for ADA X XXX
Other
Confinement X-------------------------------------------------------------------------------------------------------X
ADA: antidrug antibodies; AE: adverse event; anti-HC n  chorionic gonadotropins; BMI: body mass index; ECG: 
electrocardiogram; FSH: follicle-stimulating hormone; HBsAg: hepatitis B surface antigen; ; PK: 
pharmacokinetic.
aAdditional procedures may be performed at the investigator’s discretion. 
b Subjects will be administered a single dose of TAK-951 or matching placebo. Refer to Section 7.4.1 for further details.
cAll blood pressure and pulse assessments should be made in duplicate, and the average of both assessments should be used to cal culate the final result. The investigator can take a 
third measurement if there is inconsistency between assessments. On Day -1, vital signs will be assessed at check-in and blood pressure will be assessed again postprandially 
(approximately ±60 min after lunch, 24 hours before the Day 1 scheduled lunch, based on postdose protocol requirements). At pred ose, vital signs will be measured within 
approximately 1 hour before dosing.
dStanding blood pressure and pulse will be performed on Day -1 (postprandial), Day 1 predose (approximately 1 hour before), and at 0.5, 2, 4, 8, and 24 hours after dosing to assess 
orthostatic blood pressure and pulse. For standing blood pressure and pulse assessment, a third blood pressure and pulse assess ment will be performed after the duplicate 
semirecumbent assessment has been completed. The subject should stand still for approximately 2 minutes before this assessment.  Standing assessments must not be performed if 
semirecumbent systolic blood pressure is <85 mm Hg or if the subject presents with signs or symptoms suggestive of postural hyp otension after standing (eg, lightheadedness or 
dizziness, nausea, blurry vision) (Section 9.2.4) . 
eCollection of AEs will commence at the time the subject signs the informed consent form.
fHepatitis panel, including HBsAg and anti-HCV.
gSerum pregnancy test for female subjects only. 
hAn FSH level will be obtained to assess postmenopausal status.
iUrine PK samples will be collected at the following time intervals: predose, 0-4, 4-8, 8-12, 12-16, and 16-24 hours.
jCCICCICCI
CCICCI
Property of Takeda: For Non-Commercial Use Obo. Refer o. Refe
and the and the 
Day ay --1, v1,
heduled luduled 
ay y --1 (pos1 (po
pressure aressure
ubject shoubject s
Hg or if thHg or if 
me the sube the su
ntinti--HCV.HC
bjects onlects o
o assess po assess
llected atlected a
yo f  ly and Sand dSSS
---------------any
Onlythe AeAthplicable Terms of UseTee
FollowFollo
DaDble
4848aaplic
Appplplpl
eA p p
d Subject to th
TAK -951
Study ID TAK -951-1001 Page 14of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIAL3.2 Part 2 has been removed from the study in Protocol Amendment 04
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 15of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIAL3.3 Part 3 for MRD Cohorts 10 to 12 and 20: Days 1 Through 5 and Early Termination
Day-28 to 
-2Day
-1Days
Early 
TerminationDosing Follow -up 
Visit Day 
14±2 daysFollow -up 
Visit Day 
29±3 days Screening Predose 1 2 3 4 5 6 (Discharge)
Administrative Procedures
Informed consent X
Inclusio n/exclusion criteria X X X
Medical history/demographics X
Prior and concomitant 
medicationsX----------------------------------------------------------------- Continuous review ----------------------------------------------------------------------- X
Clinic Procedures/Assessments
Full physical examination X X X X
Height X
Weight and BMI X X
Vital signs aX X X X X X X X X X X
12-Lead ECGs X X
ECG telemetry/continuous blood 
pressure monitoringX X X X X X
TAK -951/placebo administration bX X X X X
AE monitoring X X X ----------------------------------------------------------- Continuous ------------------------------------------------------------- X
Laboratory Procedures/Assessments
Safety laboratory collection cX X X X X X X X X X
Glucose finger stick dX X X X X X
Urine drug screen X X
Alcohol breath test X
Cotinine test X X
Hepatitis screen eX
HIV test X
βhCG (pregnancy) test fX X X X
Serum FSH test gX
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 16 of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIALDay-28 to 
-2Day
-1Days
Early 
TerminationDosing Follow-up 
Visit Day 
14±2 daysFollow-up 
Visit Day 
29±3 days Screening Predose 1 2 3 4 5 6 (Discharge)
PK Evaluations
Blood sample for PK X X X X X X X X
Urine sample for PK X X X
Biomarkers
Blood sample for ADA X X X X
Other
Confinement kX--------------------------------------------------------------------------------X
ADA: antidrug antibodies; AE: adverse event; anti-HCV: antibodies to hepatitis C virus; βhCG: beta human chorionic gonadotropin; BMI: body mass index; ECG: 
electrocardiogram; FSH: follicle-stimulating hormone BsAg: hepatitis B surface antigen; ; PK: 
pharmacokinetic.
aVital signs will include body temperature, blood pressure, respiratory rate, and pulse. On dosing days, vital signs will be col lected as described in Section 3.3.1 (Part 3 Day 1 
Assessments) , Section 3.3.2 (Part 3 Da ys 2 to 4 Assessments) , and Section 3.3.3 (Part 3 Day 5 Assessments) .
bDosing regimen for TAK-951/placebo will be determined based on data from Part 1. Refer to Section 7.4.1 for further details.
cSafety laboratory will include hematology, serum chemistry, and urinalysis parameters.
dGlucose finger stick at ~3 hours postdose on each day.
eHepatitis panel, including HBsAg and anti-HCV.
fSerum pregnancy tests for female subjects only.
gAn FSH level will be obtained to assess postmenopausal status.
h
iCCICCICCICCI
CCI
CCI
Property of TakakCo-Coon-Csure, respure, re
Nonessmentsessmen )
or Ndetermineetermi
Forserum cheerum c
da: Fe on eachon eac
kedad antianti--HCH
kedmm dies to heies to ciaerciamer---------------erandndaaandndao the Applicable Terms of UseTee
FollFo
Vblca
harge)arge)cacaca
AppAppXXA
theott o  ooot
subjects ubject
fT a kd to assessto asse
om
of TComcial Use Only and Subject t
ty o
TAK-951
Study ID TAK-951-1001 Page 17 of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIALDay-28 to 
-2Day
-1Days
Early 
TerminationDosing Follow-up 
Visit Day 
14±2 daysFollow-up 
Visit Day 
29±3 days Screening Predose 1 2 3 4 5 6 (Discharge)
j
kSubjects will be confined (Section 9.5.3) .CCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to the AppApp
the AApplicable Terms of UseTee
FollFo
Vblca
harge)arge)cacaca
ot h eApp
h
TAK -951
Study ID TAK -951-1001 Page 18of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIAL3.3.1 Part 3 Day 1 Assessments
Scheduled Time
Day
-28 to -2Day
-1Day 1 (Hours)
ScreeningPre
dose
0 0.5 1 2 3 4 6Pre
dose
8 8 8.5 9 10 11 12 13 14 16 24
Administrative Procedures
Informed consent X
Inclusion/exclusion 
criteriaX X X
Medical 
history/demographicsX
Previous and 
concomitant 
medicationsX--------------------------------------------------------------- Continuous review ------------------------------------------------------- --------------------- X
Clinic Procedures/Assessments
Full physical 
examinationX X
Height X
Weight and BMI X X
Temperature and 
respiratory rateX X X X X X
Blood pressure and 
pulse a X X X X X X X X X X X X X X X X X X
Standing blood 
pressure and pulse b X X X X X X X X X X
12-lead ECGs X X X X
ECG telemetry/ 
continuous blood 
pressure monitoringX------------------------------------------------------------- Continuous monitoring ------------------------------------------------------- X
TAK -951/placebo 
administrationX X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 19 of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIALScheduled Time
Day
-28 to -2Day
-1Day 1 (Hours)
ScreeningPre
dose
0 0.5 1 2 3 4 6Pre
dose
8 8 8 . 5 9 1 01 11 21 31 41 62 4
AE monitoring X--------------------------------------------------------------Continuous review---------------------------------- -------------------------------------------X
Laboratory Procedures/Assessments
Safety laboratory 
collection c XX X X
Glucose finger stick X X
Urine drug screen X X
Alcohol breath test X
Cotinine test X X
Hepatitis screen dX
HIV test X
βhCG (pregnancy) 
test e XX
Serum FSH test fX
PK Evaluations
Blood sample for PK 
g X XXXX X X XXXXXXXX
Urine sample for PK X X X X X X
Biomarkers
Blood sample for ADA XCCI
Property oyo ffT afT aon-Commercial Use Only and Subject to the Applicable Terms of UseTeeb
99pppl
hepp
-------------hehehe
tt o  ottttttt
bject t
bjbjbj
Sbj
SSSudSddd danlylylylyly
OOneOeee
al Ue
alalalal
ercici
XXeee
ome
omomom
on-CC
ononon
of Ta
yoaTakeda: For Non
TAK-951
Study ID TAK-951-1001 Page 20 of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIALScheduled Time
Day
-28 to -2Day
-1Day 1 (Hours)
ScreeningPre
dose
0 0.5 1 2 3 4 6Pre
dose
8 8 8 . 5 9 1 01 11 21 31 41 62 4
Other
Confinement jX------------------------------------------------------------------------------------------------------------------------------ --------------------------------X
ADA: antidrug antibodies; AE: adverse event; anti-HCV: antibodies to hepatitis C virus; βhCG: beta human chorionic gonadotropin; BMI: body mass index; ECG: 
electrocardiogram; FSH: follicle-stimulating hormone HBsAg: hepatitis B surface antigen; ; PK: 
pharmacokinetic.
aAll blood pressure and pulse assessments should be made in duplicate, and the average of both assessments should be used to calc ulate the final result. The investigator can take a 
third measurement if there is inconsistency between assessments. On Day -1, vital signs will be assessed at check-in and blood pressure will be assessed again postprandially 
(approximately ±60 min after lunch, 24 hours before the Day 1 scheduled lunch, based on postdose protocol requirements). At pred ose, vital signs will be measured within 
approximately 1 hour before the first dose and 30 minutes before the second dose (ie, 8-hour TA K-951/placebo administration). A ll blood pressure and pulse assessments must be 
completed before PK blood sampling.
bStanding blood pressure and pulse will be performed on Day -1 (postprandial), Day 1 predose (approximately 1 hour before), and at 0.5, 2, 4, 8 (predose), 8.5, 10, 12, and 24 hours 
after dosing to assess orthostatic blood pressure and pulse. For standing blood pressure and pulse assessment, a third blood pr essure and pulse assessment will be performed after the 
duplicate semirecumbent assessment has been completed. The subject should stand still for approximately 2 minutes before this as sessment. Standing assessments must not be 
performed if semirecumbent systolic blood pressure is <85 mm Hg or if the subject presents with signs or symptoms suggestive of  postural hypotension after standing (eg, 
lightheadedness or dizziness, nausea, blurry vision) (Section 9.2.4) .
cSafety laboratory will include hematology, serum chemistry, and urinalysis parameters.
dHepatitis panel, including HBsAg and anti-HCV.
eSerum pregnancy tests for female subjects only.
fAn FSH level will be obtained for postmenopausal women.CCI
CCI CCI
Propertydamermermmeplicate, anlicate,
Comnts. On Ds. On
Coay 1 schey 1 sch
n-Ces before s befor
NonrN omed on Dmed on
For e and pulse and p
Foen complcomp:Falpatitis C vatitis CeO
UsUse OeOeOeO
lU s--------------Usthe Applicable Terms of UseTeeb
99pppl
hepp
thethheehehehehe
od pressurod pres
kedablurry visurry v
akedmatology,atolog
fT a ksAg and aAg and
of Tfemale suemal
ty obtained fobtained lUOnly and Subject to the
ercia
TAK-951
Study ID TAK-951-1001 Page 21 of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIALScheduled Time
Day
-28 to -2Day
-1Day 1 (Hours)
ScreeningPre
dose
0 0.5 1 2 3 4 6Pre
dose
8 8 8 . 5 9 1 01 11 21 31 41 62 4
gBlood sample for PK may be drawn 10 minutes before the second dose at 8 hours. The 24-hour sample on Day 1 is the same as the p redose sample on Day 2. Only one sample will 
be collected.
h
i
jCCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTeeb
99pppl
hepp
ot h ethe same e sam
to t
Subjthehehe
ct to
ubject
TAK -951
Study ID TAK -951-1001 Page 22of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIAL3.3.2 Part 3 Days 2 to 4 Assessments
Scheduled Time
Days 2 -4 (Hours)
Pre
dose 0 0.5 1 2 3 4 6Pre
dose
8 8 8.5 9 10 11 12 13 14 16 24
Admi nistrative Procedures
Previous and concomitant 
medicationsX-------------------------------------------------------- Continuous review ---------------------------------------------------- X
Clinic Procedures/Assessments
Full physical examination
Temperature and respiratory rate X X X X
Blood pressure and pulse aX X X X X X X X X X X X X X X X
Standing blood pressure and pulse bX X X X X X X X X
TAK -951/placebo administration c X X
ECG telemetry/continuous blood 
pressure monitoringX---------------------------------------------------------------- Continuous monitoring ----------------------------------------------- X
AE monitoring X--------------------------------------------------------- Continuous review ------------------------------------------------------------ X
Laboratory Procedures/Assessments
Safety laboratory collection dX X
Glucose finger stick X X
Pharmacokinetics Evaluations
Blood sample for PK eX X
Biomarkers
Blood sample for ADA
Other
Confinement fX----------------------------------------------------------------------------------------------------------------------------- ---------- X
AE: adverse event; ECG: electrocardiogram; PK: pharmacokinetic.
aAll blood pressure and pulse assessments should be made in duplicate, and the average of both assessments should be used to c alculate the final result. The investigator can take a 
third mea surement if there is inconsistency between assessments. At predose, vital signs will be measured within approximately 1 hour before the first dose and 30 minutes before the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 23of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIALScheduled Time
Days 2 -4 (Hours)
Pre
dose 0 0.5 1 2 3 4 6Pre
dose
8 8 8.5 9 10 11 12 13 14 16 24
second dose (ie, 8 -hour TAK -951/placebo administration). All blood pressure and pul se assessments must be completed before PK blood sampling.
bStanding blood pressure and pulse will be performed at 0.5, 2, 4, 8 (predose), 8.5, 10, 12, and 24 hours after dosing to asse ss orthostatic blood pressure and pulse. For standing blood 
pressure a nd pulse assessment, a third blood pressure and pulse assessment will be performed after the duplicate semirecumbent assessme nt has been completed. The subject should 
stand still for approximately 2 minutes before this assessment. Standing assessments must not be performed if semirecumbent systolic blood pressure is <85 mm Hg or if the subject 
presents with signs or symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, blurry vision, etc.) (Section 9.2.4 ). 
cFollow -up doses should be given at the same time as on Day 1.
dSafety laboratory will include hematology, serum chemistry, and urinalysis parameters.
e Trough sample will be collected before the first dose that day. Blood sample for PK may be drawn 10 minutes before dosing. Th e 24-hour sample on Day 1 is the same as the predose 
sample on Day 2. Only one sample will be collected.
fSubjects will be confi ned (Section 9.5.3 ).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 24 of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIAL3.3.3 Part 3 Day 5 Assessments and Early Termination
Scheduled Time
Day 5 (Hours)
Predose 0 0.5 1 2 3 4 6Pre
dose
8 88 . 59 1 01 11 21 31 41 6 2 4Day 6
(Dis
charge)Follow-
up Visit 
Day 14±2 
daysFollow-
up Visit 
Day 29 ±3 
daysEarly 
Termination
Previous and concomitant medicationsX---------------------------------------------------------------------Continuous 
review-----------------------------------------------------------------------------X
Clinic Procedures/Assessments
Full physical examination XX
Temperature and 
respiratory rate XX X XXX
Blood pressure and pulseaX X XXXXX X X X X X X X X X
Standing blood pressure 
and pulse b XX X X X X X X X X
TAK-951/placebo administration 
c XX
ECG telemetry/ continuous blood pressure monitoringX-----------------------------------------------Con tinuous --------------------------------------------------------
X
AE monitoring X--------------------------------------------------------------------------Continuous----------------------------- -------------------------------------------------------------X
Laboratory Procedures/Assessments
Safety laboratory 
collection d XX X X
Glucose finger stick X X
βhCG (pregnancy) test eXX
PK Evaluations
Blood sample for PK fXX X X X X X X X X X XXX X XX
Urine sample for PK X X X XX
Biomarkers
Blood sample for ADA gX X XCCI
Property ogtyty oyyyortytytytyFor Non-Commercial Use Only and Subject to the Applicable Terms of UseTe
licppA
14 16 16AAAp
ttthA
--------------
---------------tttttt
Subjebje
SuSuSudSudddSSS
ndS
XXay
XXlyyy
Ony
OOO
UseO
uousus-----
XXUUU
--------------ci
merermmm
Comm
XCoCoCoConn-CCC
onC
NonNNoNonnnnn
XXXXNNN
orN
XXFoororFa: F
y of Takeda:
TAK-951
Study ID TAK-951-1001 Page 25 of 91
Protocol Incorporating Amendment No. 04 23 September 2020
CONFIDENTIALScheduled Time
Day 5 (Hours)
Predose 0 0.5 1 2 3 4 6Pre
dose
8 88 . 59 1 01 11 21 31 41 6 2 4Day 6
(Dis
charge)Follow-
up Visit 
Day 14±2 
daysFollow-
up Visit 
Day 29 ±3 
daysEarly 
Termination
Other
Confinement jX------------------------------------------------------------------------------------------------------------------------------ X
ADA: antidrug antibodies; AE: adverse event; βhCG: beta human chorionic gonadotropin; ECG: electrocardiogram;
 PK: pharmacokinetic.
aAll blood pressure and pulse assessments should be made in duplicate, and the average of both assessments should be used to cal culate the final result. The investigator can take a 
third measurement if there is inconsistency between assessments. At predose, vital signs will be measured within approximately 1 hour before the first dose and 30 minutes before the 
second dose (ie, 8-hour TAK-951/placebo administr ation). All blood pressure and pulse assessments must be completed before PK b lood sampling.
bStanding blood pressure and pulse will be performed at 0.5, 2, 4, 8 (predose), 8.5, 10, 12, and 24 hours after dosing to assess  orthostatic blood pressure and pulse. For standing blood 
pressure and pulse assessment, a third blood pressure and pulse assessment will be performed after the duplicate semirecumbent assessment has been completed. The subject should 
stand still for approximately 2 minutes before this assessment. Standing assessments must not be performed if semirecumbent sys tolic blood pressure is <85 mm Hg or if the subject 
presents with signs or symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, bl urry vision, etc.) (Section 9.2.4) . 
cFollow-up doses should be given at the same time as those given on Day 1.
d Safety laboratory will include hematology, serum chemistry, and urinalysis parameters.
eSerum pregnancy tests for female subjects only.
fBlood sample for PK may be drawn 10 minutes before dosing.
gBiomarker samples for ADA testing will be taken at predose on Day 1, before discharge on Day 6, Day 14, and at follow-up visit Day 29 ±3 days. If ADAs are present, subjects may 
be asked to return for additional sample collections.
h .
i .
j Subjects will be confined (Section 9.5.3) .CCI
CCI
CCICCI CCI
Property of Takededked9.5.39.5.3 ))..a: For rOnlyly aECG: eleECG: e
OnlyeO nrage of boage of 
Use l signs wisigns w
lU sand pulsend puls
ial Ue), 8.5, 10e), 8.5
rciaent will bnt will 
mercng assessmasses
mmeon after stafter s
ommven on Dan on D
Comry, and ury, and 
on-CNonfore dosinfore dosNand SddSSdS
nd SdddSSS
and--------------ndhe Applicable Terms of UseTeebl
2424Day Da
((ca
hA
hhhhehe 
n at predoat pred
For tions.tions.aSubject to the
a: Foeda: 
TAK-951
Study ID TAK-951-1001 Page 26 of 91Protocol Incorporating Amendment No. 04 23 September 2020
4.0 INTRODUCTION
4.1 Background
TAK-951 has the potential to inhibit nausea and vomiting via neural pathways triggered by a 
variety of chemical agents and physiological signals, including the neurotransmitters dopamine, 
serotonin, and substance P.
4.2 Rationale for the Proposed Study
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, and 
pharmacokinetics (PK) of TAK-951 in healthy subjects to support further development of 
TAK-951. The study will be conducted in 2 parts: single-rising doses (SRD) will be assessed in 
Part 1 and repeat dose administration will be assessed in Part 3. Part 2 has been removed from the 
study in Protocol Amendment 04, dated 23 September 2020.
4.3 Benefit-Risk Profile
This study represents the first study in humans with TAK-951. 
The main purpose of this study in h ealthy subjects is to assess the safety and tolerability of
TAK-951; as such, no clinical benefit is expected for study participants. 
The antiemetic properties of TAK-951 have been demonstrated in different preclinical models of 
emesis in rodents, ferrets, and dogs. Based on the safety findings from nonclinical studies 
conducted with TAK-951 and human GIP infusion studies, the potential risks of TAK-951 include 
HR increase and decreased blood pressure. 
, immunogenicity, and injection site reactions and more serious hypersensitivity 
reactions are always possible.
To minimize the risks to the subjects in this study, the sponsor considers the following measures to 
be appropriate: selecting TAK-951 doses with appropriate safety margins based on nonclinical 
study data; managing study eligibility criteria; pre specifying safety monitoring procedures, such 
as frequent blood pressure assessments that include orthostatic blood pressure measurements in 
Parts 1 and 3, telemetry, and Holter electro cardiogram (ECG); developing guidance for CCI
CCI
Property reactreac
Tof Takeda: For Non-Commercial Use Only and Subjevia a neurneu
luding luding
udydyiiys tost
ealthy suealthy 
d in 2 pin 2 p
on will bn will 
4, dated  date
filee
he first se first
of this sf this 
ch, no cch, no
ttic propic pro
n rodentroden
cted witcted w
R increasincreaso f  U s e
bject to the Applicable Terms o
ty of 
TAK-951
Study ID TAK-951-1001 Page 27 of 91Protocol Incorporating Amendment No. 04 23 September 2020
investigators; and using a clinical study facility where close monitoring can be performed and 
rapid institution of appropriate care can be given when needed in a timely manner. 
Subjects with a history of serious hypersensi tivity to any medication or any component of 
TAK-951 formulation or with a hi story of significant multiple and/or severe allergies are excluded 
from this study. Subjects will be evaluated for th e development of anti-drug antibodies (ADA) as 
part of the study. The potential risks related to heart rate (HR) increase, decreased blood pressure, 
and injection site reactions will be monitored clin ically and/or with laboratory tests and have been 
considered when determining the stopping rules for this clinical study.
In addition to the potential risks associated with study drug administration, there is minimal risk 
associated with study procedures, including sc heduled periodic phlebotomy (limited to <500 mL).
Overall, the potential risks associated with the study are considered reasonable and acceptable.
5.0 STUDY OBJECTIVES AND ENDPOINTS5.1 Study Objectives
5.1.1 Study Primar y Objective
!Part 1
– To characterize the safety (including immunogenicity) and tolerability of single 
subcutaneous (SC) doses of TAK-951 in healthy sub jects.
!Part 3
– To characterize the safety (including immunogenicity) and tolerability of multiple SC 
doses of TAK-951 in healthy subjects.
5.1.2 Study Secondary Objective
!Part 1
– To characterize the PK of TA K-951 followi ng single SC doses in healthy subjects.
!Part 3
– To characterize the PK of TA K-951 following multiple SC doses in healthy subjects.
5.1.3 Study Exploratory Objectives
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecluded uded
ADA) asADA) 
od pressd pres
and havand h
here is mere is
my (limi(lim
asonableasonab
mmunogmmun
51 in  inheh
(includinnclud
altthy suhy s
ry Objry Ob
erize thrize t
o characchara
33 S
perty of T
TAK-951
Study ID TAK-951-1001 Page 28 of 91Protocol Incorporating Amendment No. 04 23 September 2020
5.2 Endpoints
5.2.1 Primary Endpoint
!Parts 1 and 3
– The primary safety endpoint of the study is safety and tolerability as assessed through 
physical examinations, vital signs, ECG/telemetry, laboratory assessments, AEs, and 
immunogenicity.
5.2.2 Secondary Endpoints 
!Part 1: plasma PK parameters for TAK-951
– Maximum observed plasma concentration (C max).
– Area under the plasma concentration time curve from time 0 to infinity (AUC ∞).
!Part 3: plasma PK parameters for TAK-951
–C maxon Day 1.
– Area under the plasma concentration-time curve during a dosing interval, where tau ( τ) is 
the length of the dosing interval (AUC τ) on Day 1.
5.2.3 Exploratory EndpointsCCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usey as asy as a
yassessassesy
Cmamaxx).).
me curveme curv
95151
centratioentrat
intervalnterva
ndpointndpoinTerms of
perty of Takeda: For Non-C
TAK-951
Study ID TAK-951-1001 Page 29 of 91Protocol Incorporating Amendment No. 04 23 September 2020
6.0 STUDY DESIGN AND DESCRIPTION
6.1 Study Design 
This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety,
tolerability, and PK of TAK-951 in healthy subjects. 
The study will consist of 2 parts (see Table 6.a) : 
!Part 1 is a FIH, randomized, double-blind, placebo-controlled, SRD study to assess the safety,
tolerability, and PK of TAK-951 in healthy volunteers. Up to 13 cohorts may be enrolled. 
Subjects will be randomized to receive TAK-951 or matching placebo.
!Part 2 of Study TAK-951-1001 has been removed from the study in Protocol Amendment 04. 
!Part 3 is a randomized, double-bli nd, placebo-contro lled, multiple-rising dose (MRD) study. 
TAK-951 and matching placebo will be administered subcutaneously. Any part of the study may 
not be conducted at the discretion of the sponsor. Safety will be assessed by monitoring for AEs, 
vital signs, ECG/telemetry, safe ty laboratory assessments after each dose and immunogenicity.
Sampling times may vary based on emerging PK data, but the maximal number of samples or the 
maximum time point will not change.
An overview of treatment cohorts is presented in Table 6.a.CCI
Property of Takeda: For Non-Commercial Use Only and Subjecutaneousaneou
will be will be
ents aftents a
ata, but ta, bu
ed ind inTaTe Applicable Terms of Useassess thsess
mayaybbyye ee
n Protocn Proto
-rirsin
tt o  t h eiplele
ect to
TAK -951
Study ID TAK -951-1001 Page 30of 91
Protocol Incorporating Amendment No. 04 23 September 2020
Table 6.a Overview of Treatment Cohorts
Cohort Regimen Treatment
Part 1
TAK -951 Placebo
1 SRD 6 2
2 6 2
3 6 2
4 6 2
5 6 2
6 6 2
13 6 2
14 6 2
15 6 2
16 6 2
17 6 2
18 6 2
19 6 2
Part 3
TAK -951 Placebo
10 MRD 6 2
11 6 2
12 6 2
20 6 2
MRD: multiple -rising dose; SRD: single -rising dose.
Part 2 of Study TAK -951-1001 has been removed from the study in Protocol Amendment 04.
6.1.1 Part 1: SRD Cohorts 1 to 6 and 13 to 19
Part 1 will consist of up to 13 cohorts of 8 healt hy subjects. Subjects in each cohort will be 
rando mly assigned to receive a single dose o f TAK -951 or placebo in a 3:1 ratio in a double -blind 
manner. Up to 104 healthy subjects will be rando mized in Part 1.
Subjects from each cohort will be admitted into the study  unit on Day  -1 and will be dosed with 
TAK -951 or m atching placebo on Day  1 after a minimum  of 8 hours of fast ing. Subjects will be 
confined for a minimum o f 30hours after dosing (can be discharged after the 30 -hour PK sample) 
and may  be confined for up to 48 hours po stdose at the discret ion of the invest igator, if needed to 
ensure subject safety . After discharge, subjects will return to the study  unit for addi tional 
assessments as indicated in the schedule of assessments (see Section 3.1). Blood sam ples for 
assessment of TAK -951 pl asma concentrations will be collected up to 48 hours postdose. Urine 
will be co llected up to 24 hours post TAK -951 dose. 
Based on agreement between the invest igator and sponsor, a staggered dosing approach may be 
used for cohorts in Part 1. After dosing the first 2 subjects of each cohort (1 receiving TAK -951 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 31 of 91Protocol Incorporating Amendment No. 04 23 September 2020
and 1 receiving placebo) the investigator will review  all available safety and tolerability data 
before dosing the remaining subjects in the cohort. The investigator will also consult Takeda as 
needed at any time.
Doses may be subject to change based on emerging PK and safety data. The sponsor may 
decide to administer lower doses, repeat doses, and cancel or add cohort(s) if deemed necessary. 
Subjects who drop out of the study for nonsafety reasons may be replaced at the discretion of the 
sponsor after discussion with the investigator.
After completion of each dosing cohort, and before selecting the next evaluable dose, a fully 
blinded assessment of the safety and tolerabili ty, laboratory results of at least 24 hours, and 
available PK data w ill be pe rformed by the site and select sponsor safety team.
Following each fully blinded dose cohort review, while the site personnel and study subjects will 
remain blinded to study drug assignment, the sponsor and select sponsor representatives may be 
unblinded to the completed cohort treatments. Precautions will be taken not to unblind the study
staff, including the investigator and the subject, until the study is completed. The blind may be 
broken before each blinded cohort review and/ or dose escalation meeting, if  necessary, due to 
safety concerns.
Study Drug Administration
In Part 1, all attempts should be made to administer the single SC dose of TAK-951 in the 
abdomen. In all cases, care should be taken to avoi d areas of scars or moles . TAK-951 must  not be 
administered into an area where the skin appears to be tender to touch, signs of bruising/bleeding 
are noted, or the area seems indurated or erythematous. When locating injection sites on the 
abdomen, avoid giving the injection in the umbilicus, ribs, hip bone. For additional information on 
study drug administration, please refe r to the study pharmacy manual.
6.1.2 Part 2
Part 2 of Study TAK-951-1001 has been removed from the study in Protocol Amendment 04.
6.1.3 Part 3: MRD Cohorts 10 to 12 and 20
Part 3 may start before the completion of Part 1. If Part 3 is started before the completion of Part 1, 
the starting dose in Part 3 will be at a dose level below that currently being studied in Part 1. 
Similar to Part 1, a staggered dosing approach may be used for cohorts in Part 3. Site personnel and 
study subjects will be blinded to study drug assignment, but selected sponsor vendors (third-party 
open) may be unblinded (Section 6.1.1) . Part 3 consists of up to 4 sequential ascending cohorts of 
healthy subjects. In each cohort, 8 healthy subjects will be randomly assigned to receive TAK- 951 
or matching placebo in a 3:1 ratio in a double-b lind manner. Up to 32 healthy subjects may be 
randomized in Part 3. 
Subjects will be admitted to the study unit on Day -1 and will be dosed on Day 1 in each 
cohort/period after a minimum of 8 hours of fasting. Subjects will be confined until Day 6, CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Termnsor mansor m
necessaecess
cretcretioion
able dosble do
east 24 st 24
ety y teamtea
rsonnel rsonn
t sponsospon
will be taill be 
study is tudy is
escalatcalat io
ministeriniste
en to aven to av
kin appekin app
ted or ered or 
tion in ton in
ease refase re
KK-951--951 1
t 3: MR3: M
y sttart beart b
ting dosing d
ilar to Pailar to P
udydy sub syyms of Use
open) open)
heaheams o
TAK-951
Study ID TAK-951-1001 Page 32 of 91Protocol Incorporating Amendment No. 04 23 September 2020
30 hours after last dose on Day 5 to assess safety, tolerability, and PK. Subjects will return after 
discharge for additional assessments as indicated in the study flow chart.
In Part 3,  safe and tolerable doses from Part 1  will be 
studied in an ascending manner. Based on emerging PK data from Part 1, adjustments to dose and 
to repeat dosing duration may be implemented. 
The schedule of assessments for Part 3 can be found in Section 3.3.
After completion of each dosing cohort, and before selecting the next evaluable dose, a fully 
blinded assessment of the safety and tolerabili ty, laboratory results of at least 24 hours, and 
available PK data will be performed by the site and select sponsor safety team.
Following each fully blinded dose cohort review, while the site personnel and study subjects will 
remain blinded to study drug assignment, the sponsor and select sponsor vendors (third-party open) 
may be unblinded to the completed cohort treatments. Precautions will be taken not to unblind the 
study staff, including the investigator and the subject, until the study is completed. The blind may 
be broken before each blinded cohort review a nd/or dose escalatio n meeting, if  necessary, due to 
safety concerns.
Subjects who drop out may be replaced at the discretion of the sponsor after discussion with the 
investigator.
Study Drug Administration
In Part 3, when administering TAK-951, injection sites must be rotated. All attempts should be 
made to administer the single SC dose of TAK-951 in  the abdomen first, followed by upper arms, 
then thigh as alternative sites, avoiding areas of scars or moles. If repeat injections of TAK-951 are 
given in the same spot, this may cause scarring and hardening of fatty tissue, which may interfere 
with the absorption of the drug; if feasible, in jections should not be given at the same location 
repeatedly. Each TAK-951 injection must be administered approximately 2 inches (5 centimeters) 
apart and must not be administered into an area where the skin appears to be tender to touch, signs 
of bruising/bleeding are noted, or the area seems indurated or erythematous. If locating injection 
sites on the abdomen, avoid giving the injection in the umbilicus, ribs, hip bone. If injecting in the 
thighs, use the outer areas, below the groin and above the knee. For additional information on 
study drug administration, please refe r to the study pharmacy manual.
6.2 Rationale for Study Design, Dose, and Endpoints
6.2.1 Rationale of Study Design 
A randomized, double-blind, placebo-controlled design for Part 1 is considered adequate to 
characterize the safety, tolerability, and PK of single doses of TAK-951. 
Part 2 of Study TAK-951-1001 has been removed from the study in Protocol Amendment 04.
Part 3 of the study is a randomized, double-blind, placebo-controlled, sequential panel MRD study 
 studied under repeat dose conditions.CCI CCI
CCI
CCIProperty of Takeda: For Non-Commercial Use Only and Subject to the Applicable e dose,dose,
t 24 hou24 ho
teamam.
nnnelel an anll
onsor veonsor
ns will s wi
he studye stud
escalatescalat i
retion otion 
1, inject, injec
se of TAe of T
ding areing a
y causecaus
rug; if feug; if 
51 injectinje
adminisdmin
g are noare n
men, avmen,
e outer aouter
adminiadmin
RatRams of Usebe e 
e and and
6.2.12.1
A rA rTermeT e
TAK-951
Study ID TAK-951-1001 Page 33 of 91Protocol Incorporating Amendment No. 04 23 September 2020
6.2.2 Rationale for Dose 
6.2.2.1 TAK-951
The starting dose for this FIH study is 20 μg and is based on the rationale detailed below.
FIH Starting Dose Consideration Based on Nonclinical Safety Study Results
The principle of the Food and Drug Administration (FDA) Guidance “Estimating the Maximum 
Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers” is to use 
a 10-fold safety factor on the no-observed-adve rse-effect-level (NOAEL) from nonclinical data to 
identify a starting clinical dose.
For TAK-951, NOAELs were identified in the 2-week Good Laboratory Practice (GLP)-compliant, 
repeat-dose toxicity studies, and no-observed-e ffect-levels (NOELs) were identified in the 
respiratory and central nervous system safety pharmacology studies. 
However, cardiovascular effects in dogs were the principal finding in the safety pharmacology
studies. In this study, the lowest dose  TAK-951 produced a transient increase in 
HR and a transient decrease in blood pressure, and a NOEL was not identified. By comparison, 
there were no effects on cardiovascular parameters in cynomolgus monkeys  
Given the reversible nature of the cardiovascular changes, variable effects between species, and 
the lack of other significant safety findings, the  TAK-951 dose is not anticipated to 
result in adverse effects.
CCICCICCICCICCIC
CI
Property of Takeda: For Non-Commercial Use Only and Subjal findinl find
TAKAK-9
a NOELNOE
ers in cyrs in 
ascular ascula
dings, thngs, t
operty of Takeda: For Non-Comrcial 
mercmmect to the Applicable Terms of Usehe Maxhe Ma
luluntnteersee
m nononclnc
ry Practiy Prac
s) were ) were
ies. es. t to
bject
TAK-951
Study ID TAK-951-1001 Page 34 of 91Protocol Incorporating Amendment No. 04 23 September 2020
Summary of FIH Starting Dose Consideration
In summary, given the totality of these findings from nonclinical safety, published literature and 
preclinical pharmacology, the proposed starting dose is CCI
CCI
CCI
CCICCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usecal safetal safehe Applicable Terms of Us
perty of TaTakeda: For Non-Commercial Use Only and SubSub
TAK-951
Study ID TAK-951-1001 Page 35 of 91Protocol Incorporating Amendment No. 04 23 September 2020
Rationale for Dosing Interval
The dosing regimens selected for Part 3 will have a projected AUC 
above for Part 1.
6.2.3 Starting Dose for This Study
Refer to Section 6.2.2.
6.2.4 Rationale for Endpoints
The PK and safety endpoints ar e standard for this type of study and are used widely and are 
recognized as reliable, accurate, and relevant. Additional PK parameters may be calculated if 
deemed necessary for the interpretation of the data.CCI
CCI
CCI
Property of Takeda: art 1.art 1.
StaS
efer to Sfer t
6.2.6.2.mmerercial Use Only and Subject to the Applicable Terms of Use
Non-Comm
For Nmens selemens se
:F o
TAK-951
Study ID TAK-951-1001 Page 36 of 91Protocol Incorporating Amendment No. 04 23 September 2020
6.2.5 Critical Procedures Based on Study Objectives: Timing of Procedures 
For this study, the following procedures are critical:
Parts 1 and 3:
!Timing of PK, blood pressure, and Holter assessments (Holter assessments in Part 1 only).
Any nonscheduled procedures required for urgent evaluation of safety concerns take precedence 
over all routine scheduled procedures.
6.3 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a phase 1 study of TAK-951 in humans, and the PK and safety profiles of the compound are 
still being elucidated. This protocol is written with some flexibility to accommodate the inherent 
dynamic nature of phase 1 clinical studies. Modifications to the dose, dosing regimen, and/or 
clinical or laboratory procedures, as outlined below,  may be required to achieve the scientific goals 
of the study objectives and/or to ensure a ppropriate safety monitoring of the study subjects.
As such, the following alterations from the currently outlined dose and/or dosing regimen may be 
permitted based on newly available data, but the maximum daily exposure, may not exceed that 
currently outlined in Section 6.2.2:
!The duration of study drug administration (eg, number of days) in the study may be decreased.
!In Parts 1 and 3, the dose of study drug administered may be repeated or decreased in 
subsequent cohorts.
!In Part 3, the dosing interval may be adjusted in subsequent cohorts 
 based on available PK data. The total exposure, however, will not exceed 
2590 h*ng/mL ( Table 6.a) .
!Instructions to take study drug with or without food or drink may be modified based on newly 
available data.
!The PK sampling scheme may be modified during the study based on newly available PK data 
(eg, to obtain data closer to the time of first occurrence of C max). If indicated, these collected 
samples may also be assayed in an exploratory manner for metabolites and/or additional 
markers.
!Up to an additional 49 mL (never more than 50 mL) of blood may be drawn for PK analyses. 
This blood volume may include repeat samples or modified PK time points based on emerging 
data. The total blood volume withdrawn from any single subject will not exceed the maximum 
allowable volume during his/her participation in the entire study.
!The timing of planned procedures for assessment of safety procedures (eg, vital signs, ECGs, 
safety laboratory tests) may be modified during the study based on newly available safety,tolerability, and PK (eg, to obtain data closer to the time of first occurrence of C
max). These CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useonlyonly).).yyy
precedepreced
in ProtPro
profiles rofile
 to accoto acc
dose, doose, d
equired tequired
momonitnito
outlined utlin
aximumximum
n (eg, nu(eg, n
rug admrug ad
may bemay b
d on avaon av
6.a6.a)).
e studystud dy
mpling smpling 
btain dabtain d
les mays may
rkers.kers.
Up to Up to
ThiTh
d
TAK -951
Study ID TAK -951-1001 Page 37of 91
Protocol Incorporating Amendment No. 04 23 September 2020
changes will not increase the number of study  procedures for a given subject during his/her 
participat ion in the ent ire study .
Addit ional laboratory  safet y tests m ay be added to blood sample s previ ously  drawn to obtain 
additional safety  information.
It is understood that the current study may emplo y some or none of the alterations described above. 
Any alterat ion made to this protocol to meet the study object ives must be detailed by the spons or in 
a letter to the study  file and forwarded to the investigator for retention. 
6.4 Study Beginning and End/Completion
6.4.1 Definition of Beginning of the Study
The overall study  begins when the first subject signs the study  informed consent form.
6.4.2 Definition of End of the Study
The overall study  ends when the l ast subject com pletes the l ast pl anned or follow -up 
visit/interact ion associated with a planned visit (this can be a phone contact), discont inues fro m the 
study , or is l ost to foll ow-up (ie, the invest igato r is unable to contact the subject).
6.4.3 Definition of Study Discontinuation
Study  discontinuation because of nonsafet y reasons, such as the fo llowing: 
A finding (eg, PK, efficacy) fro m another nonclinical or clinical study  using the study  
treatm ent(s) resul ts in the study  being stopped for a nonsafet y-related reason. 
Data from co mparator(s), drug(s) of the same class, or methodology(ies) used in this study 
beco me available and results in the study  being stopped for a nonsafety- related reason. 
The study  is stopped because of nonscient ific and nonsafet y reasons, such as slow enrollment. 
Study  discontinuation because of safet y reasons: 
Early study  terminat ion because of unanticipated concerns o f safety  to the study  subjects 
arising fro m clinical or nonclinica l studi es wi th the study  treatm ent(s), com parator(s), drug(s) 
of the sam e class, or m ethodol ogy(ies) used in this study .
6.4.3.1 Criteria for Premature Termination or Suspension of Study 
A study  site may  be terminated prematurely  or suspended if the site (includi ng the invest igator) is 
found in significant vio lation of Good Clinical Practice, protocol, or contractual agreement, or is 
unable to ensure adequate performance of the study, or as otherwise permitted by the contractual 
agreem ent.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 38of 91
Protocol Incorporating Amendment No. 04 23 September 2020
6.4.3.2 Procedures for Premature Termination or Suspension of the Study
In the event that the sponsor, an Inst itutional Review Board (IRB), or regulatory authorit y elects to 
terminate or suspend the study  or the parti cipat ion of an invest igational site, a study -specific 
procedure for ear ly terminat ion or suspensio n will be provided by  the sponsor; the procedure will 
be followed by  applicable invest igational sites during the course of terminat ion or study  
suspension.
6.4.4 Criteria for Premature Termination or Suspension of a Site
6.4.4.1 Criteria for P remature Termination or Suspension of a Site 
The study  site may be terminated prematurely  or suspended if the site (including the invest igator) 
is found in significant vio lation of Good Clinical Practices (GCP), protocol, or con tractual  
agreem ent, is unab le to ensure adequate performance of the study, or as otherwi se permitted by the 
contractual agreement.
6.4.4.2 Procedures for Premature Termination or Suspension of a Site
In the event that the sponsor, an IRB, or regulatory authorit y elects to terminate or suspe nd the 
study  or the parti cipat ion of an invest igational site, a study -specific procedure for early 
termination or suspensio n will be provided by the sponsor; the procedure will be fo llowed by  
applicable invest igational sites during the course of terminat ion or study  suspensi on.
6.4.5 Stopping Rules
The safet y assessments will provide measures of safet y and tol erabili ty of TAK -951 f ollowing 
each single and/or mult iple dose regimen. 
If notabl e AEs or safet y concerns are found at o neof the pl anned TAK -951 dose lev els, the 
principal investigator and/or the s ponsor m ay pause the dosing for safet y review and consider 
potenti al changes in the next planned dose level. Possible changes in dose administration include, 
but are not limited to:
Administrati on of  an interm ediate dose between the current and next planned dose.
Repeated administration of the current dose .
Administrati on of  a lower dose than the exist ing dose levels .
Study  terminat ion.
Notabl e AEs include:
Any SAE .
Any TAK -951 rel ated Grade 3 or hi gher AE (CTCAE versio n 5.0).
Furtherm ore, the principal invest igator and the sponsor may also consider the number and/or 
severit y of AEs as considerat ion to pause dosing or to discont inue the study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 39of 91
Protocol Incorporating Amendment No. 04 23 September 2020
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry  criteria, including laboratory  test resul ts, need to be confirmed before the first dose of 
study  drug as outlined in the Schedule of Study  Procedures in Section 3.0.
7.1 Inclusion Criteria 
The subject must understand the study  procedures and agree to participate by  provi ding wri tten 
inform ed consent. The subject must be willing and able to comply  with all study  procedures and 
restri ctions.
To be eligible for p articipat ion in this study , the subject m ust:
1.Understand the study  procedures and agree to participate by  providing wri tten informed 
consent.
2.Be willing and able to comply with all study  procedures and restrict ions.
3.Be a healt hy male or WONCBP (wo man of no nchildbearing potential) female subject aged 18 
to 55 y ears, inclusive, at the screening visit.
4.Have a BMI ≥18 and ≤30.0 (kg/m2) at the screening visit.
5.Be judged to be in good health (eg, no evidence of psychiatric, hepatic, renal, pulmo nary, or 
cardi ovascular di sease) by the invest igator, based on clinical evaluations including laboratory 
safet y tests, m edical history , physical  examinat ion, ECG, and vital sign measurements 
perform ed at the screening visit and before administration of the init ial dose of s tudy drug or 
invasive procedure.
6.Meet the fo llowing bi rth control  requi rements:
–Is a m ale subject who i s sterile or agrees to use an appropriate method of contraception, 
including a condom with or without spermicidal cream or jelly, fro m the first dose of study 
drug until 5 half -lives after the last dose of study  drug. No restri ctions are required for a 
vasectomized male subject provided the subject is at least 1 y earafter bilateral vasectomy  
procedure before the first dose of study  drug. A male subject w hose vasectomy procedure 
was performed less than 1 year before the first dose of study  drug m ust fo llow the same 
restri ctions as a nonvasectomized man. Appropriate documentation of surgical procedure 
shoul d be provi ded.
–Is a m ale subject who agrees to not donate sperm from the first dose of study drug unt il 
5half-lives after the last dose of study  drug.
–Is a female subject of nonchildbearing potential, defined by at least 1 of the fo llowing 
criteria:
–Postmenopausal  (defined as 12 -months of spontaneous ame norrhea in females 
aged >45 years or 6 months of spontaneous amenorrhea in females aged >45 years wit h 
serum follicle -stimulat ing hormone (FSH) levels >40 mIU/mL). Appropriate 
docum entati on of FSH levels is required.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 40of 91
Protocol Incorporating Amendment No. 04 23 September 2020
–Surgically sterile by  hysterectomy  and/or bilateral  oophorectomy  with appropri ate 
docum entati on of  surgical  procedure.
–Had a tubal ligat ion with appropri ate docum entati on of  surgical  procedure.
–Has a congenital condit ion result ing in no uterus.
7.2 Exclusion Criteria
Any subject who meets any  of the following cri teria will not qualify  for entry  into the study :
1.The subject has participated in another invest igationalstudy within 4 weeks (or based on local 
regul ations)before the screening visit. The 4 -week window will be derived fro m the date of 
the laststudy procedure and/or AE related to the study procedure in the previous study to the 
screening visit of the current study .
2.The subject is an emplo yee of the sponsor or studysite or immediate family  member (eg, 
spouse, parent, child, sibling) of the sponsor or studysite.
3.The subject has a history  of significant m ultiple and/or severe allergies (eg, food, drug, latex 
allergy ) or has had an anaphylact ic react ion or si gnificant intol erance to prescri ption 
ornonprescript ion drugs or food.
4.The subject ha s a known hypersensit ivity or contraindicat ion to any  com ponent of TAK -951.
5.The subject has a posit ive pregnancy test. Women of childbearing potential are not eligible for 
the study .
6.The subject isa lactating/nursing female.
7.The subject has a posit ive tes t result for hepatit is B surface ant igen, hepat itis C virus ant ibody , 
orhuman immunodeficiency antibody /antigen, at thescreening visit. Note: Subjects with 
positivehepat itis B virus orhepatit is C virus serology may be enrolled if 
quant itative polymeras e chain react ionforhepat itis B virus orhepat itis C virus ribonucleic 
acidis negat ive.
8.The subject had majo r surgery  ordonated or lost 1 unit of blood (approximately 500 mL) 
within 4 weeks before the screening visit.
9.The subject is unable to refrain fr om or anti cipates using all medications including herbal 
medicines beginning approximately 7 days before administration of the first dose of study drug, 
throughout the study until 2 days after discharge. 
10.Heavy consumpt ion of alcoho l within 3 m onths before screening ( 7 drinks/week for women, 
14drinks/week for men, where 1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] 
of beer or 1.5 ounces [45 mL] of hard liquor) or use of soft drugs (such as marijuana) within 3 
months before screening, or hard drugs (such as cocaine and phencyclidine) within 1 year 
before screening. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 41of 91
Protocol Incorporating Amendment No. 04 23 September 2020
11.The subject has used nicotine -containing products (including, but not limited to, cigarettes, 
pipes, ci gars, chewing tobacco, nicotine patch, or nicotine gum) within 28 days before 
check -in (Day -1) or cotinine test is positive at screening or Day  -1.
12.The subject has a substance abuse disorder or has a posit ive urine drug results for drugs of 
abuse at screening or Day  -1.
13.The subject has had 3 incidences of vasovagal syncope within t he last 5 y ears.
14.Subject with previous major psy choti c disorder.
15.The subject has had family  history  of unexplained sudden death or channelopathy .
16.The subject has any  clinically significant ECG findings including: long or short QT interval 
with Fridericia c orrecti on m ethod (QTcF) (over 450 msec or less than 360 msec), 
second -degree atrioventricular (AV) block type 2, third -degree AV block, bifascicular block or 
QRS ≥0.12 at screening or admissio n.
17.The subject has Brugada syndrome (RBBB pattern with ST -elevation in leads V1- V3).
18.The subject has a documented history o f sinus bradycardia (<45 bpm), sinoatrial blo ck or sinus 
pause ≥3 seconds.
19.The subject has a documented history  of any clinically  significant di sorders, including 
psychiatric, cardiovascular, nephr ological , neurol ogical, m etabo lic, and gastrointestinal 
disease including prior cholecystectomy .
20.The subject has an average semirecumbent systolic blood pressure <90 mm Hg or di astolic 
blood pressure <60 mm Hg at screening or admission.
21.The subject has an average HR <60 or >100 bpm (at screening, at Day  -1, or at predose); 
athletic subjects with an average HR <60 bpm can be enrolled only wit h medical mo nitor 
approval .
22.The subject has orthostatic hypotension defined as a decrease in systolic blood pressure 
≥20mm Hg or a decrease in diastolic blood pressure ≥10 mm Hg after 2 minutes of standing 
when co mpared with blood pressure from the sitting posit ion at screening, and at Day  -1. 
Subjects with postural orthostatic tachy cardi a, defined as HR >120 bpm standin g, will also be 
excluded.
7.3 Excluded/Allowed Concomitant Medications ,Supplements, Dietary Products
7.3.1 Concomitant Medications
The use of conco mitant m edicat ions approximately  7 days before administration of the first dose 
of study  drug, throughout the study
until 2 days after discharge is not permitted. Subjects must be 
instructed not to take any  medicat ions wit hout first consult ing with the invest igator. Any 
concomitant medicat ion use must first be discussed with the sponsor, unless the investigator or 
design ee considers immediate administration is necessitated.
The occasional use of acetaminophen (approximately <1 g/day) is allowed.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 42of 91
Protocol Incorporating Amendment No. 04 23 September 2020
7.3.2 Fruit Juice
Subjects will refrain fro m consuming grapefruit juice, grapefruits, and products containing 
grapefruit beginning approximately  2 weeks before administrati on of  the first dose of study  drug, 
throughout the study , and unt il the last PK sample has been collected.
7.3.3 Alcohol
Subjects will refrain fro m co nsuming alcoho l, 24 hours before admissio n until the final PK sample 
has been collected. Subjects may undergo an alcohol breath test at the discret ion of the 
investigator. 
7.3.4 Caffeine
In Part 1, subjects will refrain fro m consuming caffeinated beverages, 24  hours before the 
screening visit and fo llow-up visit and from 24 hours before admission and until the last PK blood 
sample has been collected in each cohort. At all other times, caffeinated beverages or 
xanthine -containing products will be limit ed to amounts of no more than 6 units per day  
(1 unit = 120 mg o f caffeine).
7.3.5 Smoki ng
Subjects will abstain from the use of tobacco -or nicotine -containing products before dosing and 
during confinement in the clinic.
7.4 Diet, Fluid, Activity 
7.4.1 Diet and Fluid
7.4.1.1 Part 1
In Part 1 of the study , subjects will fast for at least 8 hours before study  drug dosing and will 
continue to fast for an addit ional 4 hours postdose. Water is permitted. Standard meals will be 
administered at approximately 4 (lunch), 7 (snack), 10 (dinner), and 13 (snack) hours postdose on 
Day 1. Standardized m eals will be served on all other confinement day s.
7.4.1.2 Part 2
Part 2 of Study  TAK -951- 1001 has been removed fro m the study  in Protocol Amendment 04.
7.4.1.3 Part 3
In Part 3 of the study on Days 1 and 5, subjects will fast for at least 8 hours before the first dose and 
will cont inue to f ast for an addit ional 4 hours postdose. Water is permitted. Standard meals will be 
administered at approximately 4 (lunch), 7 (snack), 10 (dinner) and 13 (snack) hours postdose on 
dosing days. All meals should be served at approximately the same time each day.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 43of 91
Protocol Incorporating Amendment No. 04 23 September 2020
7.4.2 Activity
Subjects will avo id unaccustomed strenuous physical act ivity (eg, wei ght lift ing, running, 
bicycling) from the screening visit unt il administratio n of the init ial dose of study drug, throughout 
the study  (including washout i ntervals between t reatment periods), and unt il the fo llow-up visi t.
7.5 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study drug 
shoul d be recorded in the electronic case report form (eCRF) using the following categories.
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study 
drug should be recorded in the electronic case report form using the fo llowing categori es.
Pretreatment event or AE. The su bject has experienced a pretreatment event or AE that 
requi res early  terminat ion because continued part icipation imposes an unacceptable risk to the 
subject’s health or the subject is unwilling to continue because of the pretreatment event or 
AE.
Liver fu nction test (LFT) abnormalit ies.
– Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper 
limit of normal (ULN) in conjunct ion with elevated total  bilirubin >2 times the ULN.
Significant protocol  deviat ion. The discovery that the subject failed to meet protocol entry  
criteria or di d not adhere to protocol requirements, and cont inued participat ion poses an 
unacceptable risk to the subject’s healt h.
Lost to follow -up. The subject did not return to the clinic and attempts to conta ct the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
docum ents.
Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from  the study . The reason for wit hdrawal , if provided, shoul d be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal due to an AE 
shoul d not be recorded in the “vo luntary withdrawal ” category . Similarly , lack of efficacy  should 
not be recorded in the “voluntary  withdrawal” category .
Study  terminat ion. The sponsor, IRB, or regulatory agency terminates the study.
Pregnancy. The subject is found to be pregnant. Note: If the subject is found to be pregnant, the 
subject must be withdrawn immediately .
Note: The specific reasons should be recorded in the “specify” field of the electronic case report 
form.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 44 of 91Protocol Incorporating Amendment No. 04 23 September 2020
7.6 Procedures for Discontinuation or Withdrawal of a Subject
The investigator may discontinue a subject’s study participation at any time during the study when 
the subject meets the study termination criteria described in Section 7.5. In addition, a subject may 
discontinue his or her participation without giving a reason at any time during the study. Should a 
subject’s participation be discontinued, the primary criterion for termination must be recorded by
the investigator. In addition, efforts should be made to perform all procedures scheduled for the 
early termination visit. 
7.7 Subject Replacement
If a subject discontinues from the study, a replacement subject may be enrolled, if deemed 
appropriate by the investigator and sponsor. The study site should contact the sponsor for the 
replacement subject’s treatment assignment and allocation number.
8.0 CLINICAL STUDY MATERIAL MANAGEMENT8.1 Clinical Study Drug 
8.1.1 Study Drugs
In this protocol, the term study medication refe rs to all or any of the drugs defined below. 
TAK-951 SC injection and matching placebo injection will be provided to the investigator by the 
sponsor.
Details regarding the dosage form description and strengths, or composition for the 
extemporaneous preparation, of the active drug a nd placebo can be found in the pharmacy manual 
or in the referenced compounding manual when applicable. Study drug will be packaged to 
support enrollment and replacement of subjects as required.
8.1.1.1 TAK-951
The study site will be supplied by the spons or with the following medication in an open-label 
manner:
 The study medication 
will be provided in a labeled glass vial and packaged in an appropriately labeled carton with a 
single-panel label that will contain, but will not be limited to, the following: sponsor’s name and 
address, protocol number, packaging job/lot number, name and strength of the product, caution 
statement and storage conditions.
Additional reference information and administration instructions can be found in the pharmacy 
manual. 
8.1.2 Clinical Study Drug Labeling
A clinical label will be affixed to study drug containers in accordance with local regulatory
requirements.CCI
Property of Takedaovided ivided
panel lapanel 
ress, proress, pr
tatementem
AddiAddFor Non-Commercial Use Only and Subject to the Applicable Terms of Usemay y 
oululd a d a
rded byrded b
ed for thd for 
rolled, illed, i
act the sact the
s to allto al
o injectinject
criptcriptioin
e active active
ng manug man
cement emen
be supple sup
mda: Fo
TAK-951
Study ID TAK-951-1001 Page 45 of 91Protocol Incorporating Amendment No. 04 23 September 2020
8.1.3 Clinical Study Drug Inventory and Storage
Study drug must be stored in a secure, limited -access location under the storage conditions 
specified on the label and must remain in the original container until dispensed. A daily 
temperature log of the drug storage area must be maintained.
The temperature excursion information can be found in the pharmacy manual or in the referenced 
compounding manual when applicable. Receipt and dispensing of study drug must be recorded by
authorized personnel at the study site.
8.1.4 Clinical Study Drug Blinding
This is a double-blind study; the investigator and subjects are blinded to treatment assignment. An 
unblinded study drug supply will be provided to  an unblinded pharmacist or other qualified 
personnel at the study site who will blind the st udy supplies. Treatment identity (name and strength 
or potency) will be included on th e study drug container label. Rando mization code/disclosure 
envelopes or lists will be provided per the standard operating procedures of the study site.
After completion of each dosing cohort, and before selecting the next evaluable dose, a fully 
blinded assessment of the safety and tolerabili ty, laboratory results of at least 24 hours, and 
available PK data will be performed by the site and select sponsor safety team.
Following each fully blinded dose cohort review, while the site personnel and study subjects will 
remain blinded to study drug assignment, the sponsor and select sponsor vendors (third-party open) 
may be unblinded to the completed cohort treatments. Precautions will be taken not to unblind the 
study staff, including the investigator and the subject, until the study is completed. The blind may 
be broken before each blinded cohort review and/or dose escalation meeting, if necessary, due to 
safety concerns.
8.1.5 Randomization Code Creation and Storage 
Randomization personnel of the sponsor or designee will generate the randomization schedule. All 
randomization information will be stored in a secured area, accessible only by authorized 
personnel.
8.1.6 Clinical Study  Blind Maintenance/Unblinding Procedure
The study drug blind will be maintained through a randomization schedule held by the unblinded 
pharmacist at the study site or by the sponsor. The study drug blind shall not be broken by the 
investigator unless information concerning the st udy drug is necessary for the medical treatment of 
the subject. If possible, the medical monitor should be contacted before the blind is broken. 
Unblinding will be performed per the standard operating procedures of the study site.
8.1.7 Accountability and Destruction of Sponsor-Supplied Drugs
The investigator and investigator’s designated site pharmacy must ensure that the sponsor or 
contract research organization (CRO) supplied drug is used in accordance with the protocol and CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usethe refethe re
st be rect be r
d to treato tre
armacistrmaci
eatment eatmen
bel. Randl. Ran
ating proating p
electingelectin
laboratoaborat
and seland se
eview, wview
t, ththe spe s
ohort trehort 
ator andor an
cohort rohort
on Codn Cod
rsonnel oonnel
nformatnform
ClinicClini
e studystudy dy
pharmacharm
invesinve
thth
TAK -951
Study ID TAK -951-1001 Page 46of 91
Protocol Incorporating Amendment No. 04 23 September 2020
pharmacy manual and is dispensed only to subjects enro lled in the study. To document appropriate 
use of the sponsor supplied drugs (TAK -951 vials), the invest igator pharmacy/site must maintain 
records of drug delivery t o the site, site inventory, dispensat ion and use by each subject, and return 
to the sponsor or designee. 
Upon receipt of sponsor -supplied drug, the designated blinded pharmacist must verify the contents 
of the shipments against the packing list. The verif ier should ensure that the quantit y is correct, and 
the medicat ion is in good condit ion. If quantit y and condi tions are acceptable, designated site 
pharmacist should acknowledge the receipt of the shipment by signing bottom half o f the packing 
list. If the re are any  discrepancies between the packing list versus the actual product received, 
Takeda must be contacted to resolve the issue. The packing list should be filed in the invest igator’s 
essent ial docum ent file.
The invest igator’s designated blinded pharm acist must m aintain 100% accountabilit y for all 
sponsor -supplied drugs received and dispensed during his or her ent ire parti cipat ion in the study. 
Proper drug accountabilit y includes, but is not limited to:
Moni toring expirat ion dates.
Frequent ly verifying that actual  inventory  matches docum ented inventory .
Verifying that the drug accoun tabilit y log is completed for each prepared dose.
Verifying that all containers used are documented accurately on the log.
Verifying that required fields are co mpleted accur ately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
8.2 Ancillary Supplies
All ancillary supplies will be provided by eit her the study  site or the sponsor or desi gnee, 
depending upon availabili ty. The list of ancillary  supplies and source information can be found in 
the pharmacy  manual or in the referenced compounding manual when applicable. If provided by 
the sponsor, unused ancillary supplies will be accounted for and disposed of as directed b y the 
sponsor or designee.
9.0 STUDY PROCEDURES
The fo llowing sect ions describe the study  procedures to be performed and data to be collected as 
indicated in the schedule of study procedures (Sectio n 3.0). For each procedure, subjects are to be 
assessed by  the same investi gator or si te personnel whenever possible. Please note that it may  
beco me necessary  to perform  the f ollowing procedures at unscheduled time periods, per the 
discreti on of  the invest igator.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 47of 91
Protocol Incorporating Amendment No. 04 23 September 2020
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
Inform ed consent m ust be obtained before the subject enters into the study  and before any 
protocol -directed procedures are performed. The requiremen ts of inform ed consent are described 
in Appendix B.
9.1.1.1 Assignment of Screening and Randomization Numbers 
All consented subjects will be given a unique screening number that will be used to identify the 
subject for all procedures that occur before randomizat ion or allocat ion. Each subject will be 
assigned only one screening number. Screening numbers must not be reused for different subjects. 
Any subject who is screened mu ltiple times will be assigned a new screening number for each 
screening event.
All eligible subjects will be rando mly allocated and will receive a rando mizat ion number. The 
rando mizat ion number identifies the subject for all procedures occurring after randomizat ion. 
Once a rando mizat ion number is assigned to a subject, it can never be reassigned to another subject. 
A single subject cannot be assigned more than one rando mizat ion number.
9.1.1.2 Study Drug Assignment
On Day  1, subjects will  be assigned a rando mizat ion number in ascending numerical order at the 
clinical site. The rando mizat ion number encodes the subject assignment to either TAK -951 or 
placebo, according to the randomizat ion schedule generated before the study. Each subject will be 
dispensed blinded study  drug, labeled wi th his/her unique rando mization number, throughout the 
study .
9.1.2 Inclusion and Exclusion 
Each subject will be assessed through randomization, according to the eligibilit y criteria provi ded 
in Section 7.0.
9.1.3 Medical History/ Demography
Qualified site personnel will collect subject significant medical history  (past and concurrent 
medical condit ions), per the clinical site’s standard of care and appropri ate clinical judgment, and 
subject demographics.
Qualified site personnel will review subject prior and conco mitant m edicat ion use. Medicat ions 
are defined as prescription and over -the-counter drugs, vaccines, supplements, nutraceuticals, and 
oralherbal preparations.
9.2 Clinical Procedures and Assessments
9.2.1 Full Physical Examination
Qualified site personnel will conduct full physical examinat ions.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 48of 91
Protocol Incorporating Amendment No. 04 23 September 2020
9.2.2 Height and Weight
Body  weight and height will be obtained with the subject’s shoes off, and jacket or coat removed.
9.2.3 Body Mass Index
Body  mass index (BMI) equals a subject’s weight in kilograms divided by height in meters 
squared (BMI = kg/m2). BMI will be rounded to the nearest whole number according to the 
standard convent ion of 0.1 to 0.4, round down, and 0. 5 to 0.9, round up.
9.2.4 Vital Signs
Body  temperature will be measured with eit her an oral (temperature taken at floor of the mouth) or 
tympanic thermo meter. The same method (ie, oral or tympanic) must be used for all measurements 
for each individual subject an d shoul d be the same for all subjects. At predose, vital signs will be 
measured within approximately 1 hour predose.
Subjects should rest in a semirecumbent position for at least 3 minutes before vital signs are 
measured. Vi tal signs will include pulse rat e (beats per minute [bpm]), respiratory  rate, and 
systolic and diastolic blood pressure in all parts of the study. Blood pressure and pulse assessments 
shoul d be made in duplicate with an interval of approximately  2 minutes between the 2 
assessments. The P I can take a third BP assessment if results are inconsistent. The final BP read 
out shoul d be the average of these assessments. 
For orth ostati c blood pressure and pulse assessment, a third blood pressure and pulse assessment 
with the subject standing will be performed after the duplicate semirecumbent assessment has bee n 
completed. The subject should stand st ill for approximately  2 minutes before thi s assessment.
Standing assessments must not be performed if semirecumbent systolic blood pressure is <85 mm 
Hg or if the subject presents with signs or symptoms suggest ive of postural hypotension after 
standing (eg, lightheadedness or dizziness, nausea, blurry visio n, etc).
The same method (eg, same size cuff, manual or automated) must be used for all measureme nts for 
each individual subject and should be the same for all subjects.
Subjects should cont inue to rest in a semirecumbent posit ion from the time o f dosing unt il 4hours 
postdose except to stand for the measurement of standing vital signs (if needed) or other 
study -related procedure.
When vital signs are scheduled at the same t ime as blood draws, they will be obtained before the 
scheduled blood draw.
9.2.5 Glucose 
Blood gl ucose will be monitored using finger -stick blood samples in Parts 1 and 3 and will also b e 
monitored using safet y laboratory  testing.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 49of 91
Protocol Incorporating Amendment No. 04 23 September 2020
9.2.6 ECG Procedure
9.2.6.1 Screening and Safety ECGs
A 12 -lead ECG will be co llected at the time po ints specified in the Schedule of Study  Procedures 
(see Section 3.0). 
The invest igator will interpret the safet y ECG using 1 of the fo llowing categori es: wi thin normal  
limits, abnormal but not clinically significant, or abnormal and clinically significant. The time that 
the ECG was perfo rmed will  be recorded.
The fo llowing param eters will  be recorded on the eCRF from the subject’s ECG trace: HR, RR 
interval , QRS interval, PR interval, QT interval, and QTcF.
The invest igator will be responsible for providing the interpretation of all safety  ECGs 
(norm al/abnorm al). These results will be reviewed by  the investi gator f or subject safet y and will 
be provided in an appropriate format with the clinical study  report.
Ad hoc 12 -lead ECGs will also be required, if a subject complains of palpitat ions, dizziness, 
breathlessness, chest tightness or any  other symptoms suggest ive of arrhyt hmia, between Day 1 
(postdose) and discharge. Pulse will be checked immediately, and if it is greater than 120 bpm, a 
12-lead ECG, blood pressure and pulse will be m easured and recorded. The ECG, blood pressure 
and pulse measurements will be reviewed by the Investigator, who will use clinical judgment 
regarding further monitoring and management.
9.2.6.2 Telemetry
In Parts 1 (SRD) and 3 (MRD), cardiac mo nitoring (pulse and ECG ) will be assessed via telemetry 
and will be performed for approximately 2 hours before dosing through to approximately 24 hours 
postdose.
Subjects should remain sitt ing or supine for at least 5 minutes before each telemetry  reading. At 
the 0-hr timepo int,telemetry  may be assessed in the semirecumbent posit ion to allow for the most 
efficient capture of the other mult iple assessments. 
9.2.6.3 Holter
The 12 -lead Ho lter ECG monitoring will be captured on Day 1 of Part 1 (SRD) with a minimum o f 
23.5 hours of continuo us cardi ac m onitoring. Continuous 12 -lead Holter ECG monitoring will be 
perform ed from 1 hour predose until 24 hours postdose. For all postdose ECG collect ions, three 
10-second ECGs will be extracted at each extraction window time point. 
ECG extraction t ime points will occur before PK blood draws. Accordingly, subjects will be 
supervised and quiet ly rest ing supine beginning a minimum o f 10 minutes before each actual ECG 
extracti on window of 10 minutes. Subjects will be supervised while remaining at rest, quiet, and 
awake and in a supine posit ion from at least 10 minutes before the beginning of each ECG 
extracti on time point and will remain quiet, awake, motionless, and supine for at least 10 minutes 
after the beginning of each ECG extraction time point.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 50 of 91Protocol Incorporating Amendment No. 04 23 September 2020
9.2.7 Study Drug Administration
Study Drug (TAK-951) will be administered as shown in the Schedule of Study Procedures in 
Section 3.0.
9.2.9 AE Monitoring
AE monitoring begins after signing of the informed consent form. Changes in subject health status 
from the baseline assessment until study drug administration should be captured in the subject’s 
medical history. A complete description of AE co llections and procedures is provided in Section 
10.0.
9.3 Laboratory Procedures and Assessments
Laboratory samples will be collected in accordance with acceptable laboratory procedures. 
Samples will be collected following a minimum 8-hour overnight fast at the time points stipulated 
in the schedule of study procedures (Section 3.0).
9.3.1 Hematology
Hematology will consist of the following tests:
Erythrocytes (red blood cells [RBCs]) Hemoglobin
Hematocrit Platelets
Leukocytes (white blood cells [WBCs] with absolute
differentialCCICCI
Property of Takeda: For Non-Commercial Use Only and Subjecnsent forsent fo
nistratiostrat
ollectionllectio
Assessmssessm
d in accoin ac
ng a ming a m
dures (Sures (
sist of thsist of
od cells d cellN
Fo
white blohite b:Applicable TeyProcedProceUse
keect to the ApTerms of U
TAK -951
Study ID TAK -951-1001 Page 51of 91
Protocol Incorporating Amendment No. 04 23 September 2020
9.3.2 Chemistry 
Chemistry  evaluat ions will consist of the fo llowing chemistry  panel:
Albumin Alkaline phosphatase
ALT AST
Blood urea nitrogen Calcium
Carbon dioxide Chloride and lipase
Creatinine Glucose 
Gamma -glutamyl transferase Sodium
Potassium Bilirubin (total) if above the upper limit of normal, total 
bilirubin will be fractionated
Protein (total)
ALT: alanine aminotransferase; AST: aspartate aminotransferase
If subjects experience ALT or AST >3 times the ULN, fo llow-up laboratory  tests (at a minimum, 
serum  alkaline phosphatase, ALT, AST, total bilirubin, gamma-glutamyl transferase, and 
internat ional normalized ratio) should be performed 24 hours after the abnormalit y was noted, and 
the medical mo nitor shoul d be contacted .
If ALT or AST remains elevated >3 times the ULN, the invest igator must contact the medical 
monitor for consideration of addit ional testing, close monitoring, possible discont inuat ion of study 
drug, and discussio n of the relevant subject details and possi ble alternat ive etio logies. The 
abnorm ality should be recorded as an AE.
Please refer to Section 7.5for subject discont inuat ion criteria regarding abnormal liver t est results 
and Sect ion10.2.8.5 for guidance on reporting abnormal liver test results.
9.3.3 Urinalysis
Urinalysis will consist of the fo llowing tests:
Protein Glucose
Blood Nitrate
Urine microscopy  will be perform ed if urinalysis is abnormal. Microscopy  consists of 
RBC/high -power field, WBC/high -power field, and casts.
9.3.4 Diagnostic Screening
Other 
HIV Hepatitis screen (hepatitis B surface antigen, hepatitis C 
virus ant ibody)
FSH βhCG (pregnancy) test
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 52 of 91Protocol Incorporating Amendment No. 04 23 September 2020
Alcohol Screen
Subjects will undergo an alcohol breath test. A urine alcohol test may be performed at the 
discretion of the investigator.
Urine
The urine drug screening assessment will include the following tests:
Amphetamines 3,4-methylenediox y-methamphetamine
Barbiturates Methadone/metabolite
Benzodiazepines Opiates
Buprenorphine/metabolite Oxycodone/oxymorphone
Cannabinoids Phencyclidine
Cocaine/metabolites
9.4 PK, , and Immunogenicity Samples
Samples for PK, ADA  analysis will be collected as specified in the Schedule 
of Study Procedures (Section 3.0). Please refer to the laboratory manual for information on the 
collection, processing, and shipment of s amples to the central laboratory.
The decision as to which plasma and/or serum samples collected will be assayed for evaluation of 
PK will be determined by the sponsor (eg, samples at lower doses may not be assayed if samples at 
higher doses reveal undetectable drug concentrations). CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useneele ab
plic
Apeth
tt o
unogeniunogen
ill be coll be c
he laborlabo
to the ceo the
m sampm sam
samplesampl
concentoncen
rcial 
TAK-951
Study ID TAK-951-1001 Page 53 of 91Protocol Incorporating Amendment No. 04 23 September 2020
Primary specimen collection par ameters are provided in Table 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary 
Specimen 
Derivative Description of Intended UseSample 
Collection
Plasma sample for PK Plasma Plasma PK measurement Mandatory
Urine sample for PK Urine Urine PK measurement Mandatory
Blood sample for ADA Blood Blood ADA analysis Mandatory
ADA: anti-drug antibody;
aA single follow-up optional sample will be collected.
9.4.1 PK Measurements 
The PK parameters of TAK-951 will be determined from the concentration-time profiles for all 
evaluable subjects. Actual sampling times, rather than scheduled sampling times, will be involved 
in all computations involving sampling times.CCICCI
CCI
CCI
Property of Takeda: For Non-Commercial Ucollectedcollec
s 
AKK-se Only and Subject to the Applicable Terms of Useample ample 
CollectioCollectso
MandMeT
Mbbb
lic
95195
ctual samual s
invonvolvilvUsese Only and Subject to the App
akeda: For 
TAK -951
Study ID TAK -951-1001 Page 54of 91
Protocol Incorporating Amendment No. 04 23 September 2020
The fo llowing pl asma PK parameters will be determined after single dose and at steady  state: 
Symbol/Term Definition
Plasma/Blood/Serum
AUC 24 Area under the plasma/blood/serum concentration -time curve from the time 0 to time 24 
hours. 
AUC τ Area under the plasma/blood/serum concentration -time curve during a dosing interval, where 
tau (τ) is the length of the dosing interval.
AUC last Area under the plasma/blood/serum concentration -time curve from time 0 to time of the last 
quantifiable concentration.
AUC ∞ Area under the plasma/blood/serum concentration -time curve from time 0 to infinity, 
calculated as AUC ∞=AUC t+C last/λz
R Accumulation ratio (index) calculated as AUCτ at steady state/AUC∞after a single dose.
Rac(AUC) Accumulation ratio (based on AU C), calculated as AUC τat steady state/AUC τafter a single 
dose.
Cmax Maximum observed plasma/blood/serum concentration.
Cmax,ss Maximum observed steady -state plasma/blood/serum concentration during a dosing interval.
CL/F Apparent clearance after extra vascular administration, calculated as = Dose/AUC ∞after a 
single dose and as Dose/AUC τafter multiple dosing (at steady state).
λz Terminal elimination rate constant calculated as the negative of the slope of the log -linear 
regression of the natural loga rithm concentration -time curve during the terminal phase.
t1/2z Terminal disposition phase half -life calculated as ln(2)/λ z.
tlag Lag time to first quantifiable concentration.
tmax Time of first occurrence of C max.
Vz/F Apparent volume of distribution during the terminal disposition phase after extravascular 
administration, calculated as (CL/F)/λ z.
The following urine PK parameters of TAK -951 will be determined after SD administration in Part 
1:
Urine
Aet1-t2 Amount of drug excreted in urine from time 1 to time 2, calculated as C ur×Vur, where C uris 
the concentration of drug excreted in urine and V uris the volume of urine excreted.
Aet Total amount of drug excreted in urine from time 0 to time t.
Aeτ Amount of drug excreted in urine during a d osing interval (τ) at steady state.
fe Fraction of drug excreted in urine, calculated as (Ae t/dose) ×100. Molecular weight 
adjustment needed for metabolites.
CL R Renal clearance calculated as Ae 0-24/AUC 24.
Addit ional PK parameters may be calculated as appropriate. Further details will be provided in the 
clinical pharmaco logy analysis plan.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 55 of 91Protocol Incorporating Amendment No. 04 23 September 2020
9.4.1.1 Plasma or Serum for PK Measurements
Blood samples for PK analysis of TAK-951 will be collected into chilled blood collection tubes 
(vacutainer) containing the anticoagulant K2EDTA. The collected blood samples may be archived 
for additional analysis of potential metabolites.
The actual time of sample collection will be recorded on the source document and eCRF. Sampling 
time points may be adjusted based on the preliminary emerging concentration data collected from 
prior subject(s), but the total number of samples collected per subject should not exceed the 
planned number.
9.4.1.2 PK Sample Analysis
Plasma and urine concentrations of TAK-951 will be measured by a validated high-performance 
liquid chromatography with tandem mass spectrometry assay.
9.4.2 Immunogen icity (ADA) Measurements 
Protein products have the potential to induce anti-drug immune response which may affect the 
safety and efficacy of the compound under study. Detection and analysis of ADA formation is a 
helpful tool in understanding drug immunogenicity, efficacy, and safety. To understand drug 
immu mples will be collected on Day 1, predose, and at the follow-up visit. 
Othe have reported the formation of ADAs, however, an ADA assay may be 
influenced by several factors including assay methodology, sample handling, timing of sample 
collection, concomitant medications, and underlying disease. Therefore, the inciden ces of ADA 
formation cannot be directly compared with the other products. ADA samples will be taken in all 
parts of the study across all cohorts.
9.4.3 Biomarker Measurements
CCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useved d 
SampliSamp
ollected ollecte
xceed thxceed 
validatedalidate
mmune rmune 
ection anction a
, efficacffica
d on Dayon D
formatiormati
ay methy m
d underd unde
d wid withtiiih
ts.
uremenreme
operty of Takeda: For Non-Com
TAK-951
Study ID TAK-951-1001 Page 56 of 91Protocol Incorporating Amendment No. 04 23 September 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseProperty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of U
TAK-951
Study ID TAK-951-1001 Page 57 of 91Protocol Incorporating Amendment No. 04 23 September 2020
9.5 Confinement
9.5.1 Part 1 (SRD)
Subjects will report to the clinical site the evening before the scheduled day of study drug 
administration (Day  -1). Sub jects will remain in the clinic for 30 hours postdose (Day 2) or until 48 
hours postdose if requested by the investigator and deemed necessary to ensure subject safety. At 
the discretion of the investigator, subjects may be requested to remain in the clinical site longer.
9.5.2 Part 2 (SD Apo Challenge)
Part 2 of Study TAK-951-1001 has been removed from the study in Protocol Amendment 04.CCI
Property of TakedaConfCon
5.1.1
SubjeSub
adaUse
da: For Non-Commercial Use Only and Subject to the Applicable Terms of Us
TAK -951
Study ID TAK -951-1001 Page 58of 91
Protocol Incorporating Amendment No. 04 23 September 2020
9.5.3 Part 3 (MRD)
Subjects will report to the clinical site the evening before the scheduled day  of study  drug 
administration ( Day -1). Subj ects will remain in the clinic from Day -1 unt il discharge on Day 6. 
Subjects will be discharged 30 hours after last dose of TAK- 951/pl acebo. At the discret ion of the 
investigator, subjects may  be requested to rem ain in the study  site longer.
9.6 Childbearing Status and Methods of Contraception
9.6.1 Women of Childbearing Potential
Women of childbearing potential will be excluded fro m this study .
9.6.1.1 Definition of Women of Childbearing Potential
A wo man is considered of childbearing potential (ie, fertile) fo llowing menarche and unt il 
beco ming postmenopausal, unless permanent ly sterile.
9.6.2 Women of Nonchildbearing Potential
A female subject of nonchildbearing potential is defined as sat isfying at l east 1 of the fo llowing 
criteria:
Postmenopausal: At l east 12 m onths of spontaneous amenorrhea and a FSH 
concentration >40  mIU/mL.
Surgically sterile by  hysterectomy  and/or bilateral  oophorectomy  with appropri ate 
docum entati on of  surgical  procedure.
Has no uterus as a result of a congenital condit ion.
9.6.2.1 Contraception fo r WONCBP
No contraception is required for WONCBP.
10.0 ADVERSE EVENTS
10.1 Definitions and Elements of AEs
An AE is defined as any untoward medical occurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a study; it does not necessarily have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whet her or 
not it is considered related to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 59of 91
Protocol Incorporating Amendment No. 04 23 September 2020
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG param eters maybe considered AEs if they are judged to 
be clinically  significant (i e, if som e act ion or intervent ion is required or if the investigator 
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  
re-test and/or continued monitoring of an abnormal value are not considered an intervention. In 
addition, repeated or addit ional noninvasive t esting for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal fail ure), the di agnosis only  should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory test, ECG, x -ray) should NOT be recorded as an AE unless related to 
a study  procedure. However, if the subject experiences a worsening or complicat ion of such a 
concurrent medical history  condi tion, the worsening or com plicat ion should be recorded 
appropriately  as an AE (worsening or complicat ion occurs after informed consent is signed). 
Invest igators should ensure that the event term recorded captures the change in the condit ion 
(eg, “worsening of…”).
If a subject has a pre -exist ing episodic condit ion (eg, asthma, epilepsy), any occurrence of an 
episode should only be captured as an AE if the episodes beco me more frequent, serious, or 
severe in nature, that is, invest igators should ensure that the AE term recorded captures the 
change from baseline in the condit ion (eg “worsening of…”).
If a subject has a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion shoul d only  be captured as an AE if occurring to a greater exten t 
than that which would be expected. Again, invest igators should ensure that the AE term 
recorded captures the change in the condit ion (eg, “worsening o f…”).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 60of 91
Protocol Incorporating Amendment No. 04 23 September 2020
Worsening of AEs:
If the subject experiences a worsening or complicatio n of an AE aft er the first administration of 
study  medicat ion or after any  change in study  medicat ion, the worsening or complicat ion 
shoul d be recorded as a new AE. Invest igators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Chan ges in severit y of AEs:
If the subject experiences a change in the severit y of an AE that is not associated with a change 
in study  medicati on, the event shoul d be captured once with the maximum severit y recorded.
Prepl anned surgeries or procedures:
Prepl anned procedures (surgeries or therapies) that were scheduled before signing of informed 
consent are not considered AEs. However, if a preplanned procedure is performed early (eg, as 
an emergency) due to a worsening of the pre -exist ing condit ion, the worseni ng of the condit ion 
shoul d be captured appropriately as an AE. Complications result ing fro m any planned surger y 
shoul d be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical con dition 
shoul d not be recorded as AEs but should be documented in the subject’s source documents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a study  subject, at a dose above that which is assigned to that individual subject 
according to the study protocol. It is up to the investigator or the reporting physician to decide 
whether a dose is to be considered an o verdose, in consultation wit h the sponsor.
All cases of overdose (with or without associated AEs) will be documented on an overdose 
page of the eCRF, to capture this important safet y inform ation consistently in the database. 
AEs associated with an overdose will be documented on AE CRF(s) according to Section 10.0.
Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Sect ion 10.2.8 .
In the event of drug overdose, the subject should be treated symptomat ically.
10.1.1 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 61of 91
Protocol Incorporating Amendment No. 04 23 September 2020
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were more severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT assessed by the invest igator or sp onsor, that satisfies 
any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Includes an y event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
Table 10.a T akeda Medically Significant AE List
Term
Acute respiratory failure/acute respiratory 
distress syndromeHepatic necrosis
Acute liver failure
Torsade de pointes/ventricular fibrillation / 
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal product Toxic epidermal necrolysis/
Stevens -Johnson syndrome Neuroleptic malignant syndrome/malignant hyperthermia
Spontaneous abortion/stillbirth and fetal death
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and fo llowed up in the same manner (see Sections 10.1 and 10.1.1 ).
10.1.2 Special Interest AEs
AEs of special interest for TAK -951 include inject ion site reactions, hypotension, and tachycardia. 
These AEs will be monitored by  the invest igator and sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 62of 91
Protocol Incorporating Amendment No. 04 23 September 2020
10.2 AE Procedures
10.2.1 Assigning Severity of AEs
All AEs, including clinically  significant treatm ent-emergent laboratory  abnorm alities, will be 
graded according to NCI CTCAE v5.0. AEs not listed by  the NC I CTCAE will be graded as 
displayed in Table 10.b.
Table 10.b NCI CTCAE
Grade Description
1 Mild; asy mptomatic or mild symptoms; clinical or diagnostic observations
only; interventio n not indicated.
2 Moderate; minimal, local, or noninvasive intervention indicated; limiting
age-appropriate instrumental activities of daily living (ADL).
3 Severe or medically signific ant but not immediately life -threatening;
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -care ADL.
4 Life-threatening consequences; urgent intervention indicated.
5 Fatal AE; an event that results in the death of the subject.
NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.
10.2.2 Assigning Causality of AEs
The rel ationship of each AE to study  medicati on will  be assessed using the following categories:
Related: An AE that fo llows a reasonable tem poral  sequence from  administrati on of  a 
drug (including the course after withdrawal o f the drug), or for which a causal 
relationship is at least a reasonable possibilit y, ie, the relati onship cannot be 
ruled out, al though factors other than t he drug, such as underlying diseases, 
complicat ions, conco mitant drugs, and concurrent treatments, may also be 
responsible.
Not Rel ated: An AE that does not follow a reasonable temporal sequence fro m ad ministration 
of a drug and/or that can reasonably be explained by  other factors, such as 
underlying diseases, complicat ions, conco mitant medi cations, and concurrent 
treatm ents.
10.2.3 Start Date 
The start date of the AE is the date that the first signs/symptoms were noted by  the subject and/or 
investigator.
10.2.4 End D ate 
The end date of the AE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 63of 91
Protocol Incorporating Amendment No. 04 23 September 2020
10.2.5 Pattern of AE (Frequency) 
Episodi c AEs (eg, headache) or those which occur repeatedly over a period of consecutive days are 
intermittent. All other events are continuous.
10.2.6 Action Taken With Study Treatment
Drug withdrawn –a study  medicat ion is stopped due to the particular AE.
Dose not changed –the particular AE did not require stopping a study  medicat ion.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not applicable –a study  medicat ion was stopped for a reason other than the particular AE
(eg,the study  has been terminated, the subject died, dosing wit h study  medicat ion had not y et
started or dosing wit h study  medicat ion was already  stopped before the onset of the AE).
Drug interrupted –the dose was interrupted due to the particular AE.
10.2.7 Outcome 
Recovered/reso lved –subject returned to first assessment status with respect to the AE.
Recovering/resolving –the intensit y is lowered by  one or m ore stages: the diagnosis has or
signs/symptom s have almost disappeared; the abnormal laboratory value improved but has not
returned to the normal range or to the baseline value; the subject di ed from a cause other than
the particular AE with the condit ion rem aining “recovering/reso lving.”
Not recovered/not resolved –there is no change in the diagnosis, signs, or symptoms; the
intensity of the di agnosis, signs/symptoms or laboratory  value on th e last day  of the observed
study peri od has beco me worse than when it started; is an irreversible congenital ano maly; the
subject died fro m another cause with the particular AE state remaining “Not recovered/not
resolved.”
Recovered/reso lved with sequelae –the subject recovered fro m an acute AE but was left with
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with
some persisting paresis).
Fatal  –an AE that is considered as the cause of death.
Unknown –the course of the AE cannot be fo llowed up due to hospi tal change or residence
change at the end of the subject’s participation in the study .
10.2.8 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs
10.2.8.1 Collection Period
Collect ion of AEs ( ie, AEs, SAEs, special interest AEs, and abnormal LFTs) will co mmence at the 
time the subject signs the informed consent. Routine co llection of AEs will cont inue unt il 
approximately  30 days after the last dose of invest igational product. For subjects who discont inue 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 64of 91
Protocol Incorporating Amendment No. 04 23 September 2020
before the administration o f study medicat ion, AEs will be fo llowed unt il the subject discont inues 
study  participati on. 
10.2.8.2 Reporting AEs
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have y ou been feeling since y our l ast visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing an 
SAE before the first exposure to investigational product must be monitored until the symptoms 
subside and any  clinically  relevant changes in laboratory  values have returned to baseline or there 
is a satisfactory explanat ion for the change. Nonserious AEs that begin before the first exposure to 
investigat ional product, related or unrelated to the study pro cedure, need not be fo llowed up for the 
purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medicat ion 
or not, m ust be m onitored until the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to baseline or until there is a sat isfactory  explanat ion for the 
changes observed. All AEs will be documented in the AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug treatm ent. The fo llowing informat ion 
will be documented for each event:
Event term .
Start and end date and time.
Pattern of AE (frequency).
Severit y/Intensi ty.
Causalit y (investi gator’s opi nion of the causal relatio nship between the event and 
administration of s tudy drugs).
Action taken with study  drug.
Outcom e of event.
Seriousness.
10.2.8.3 Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A Takeda SAE form must be co mpleted, in English an d signed by the invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject identificat ion number.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 65of 91
Protocol Incorporating Amendment No. 04 23 September 2020
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Appendix 14.1.1 .
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  parti cipat ion.
Reporting of S AEs that begin before first administration of investigational product will fo llow the 
same procedure for SAEs occurring on treatment.
SAE Follow -Up
If informat ion is not available at the time o f the first report becomes available at a later date, the 
investigator should complete a fo llow-up SAE form  or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem resul ts) shoul d be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.2.8.4 Management of Specific AEs
Sinus Tachycardia
CTCAE Grade Management
CTCAE Grade 2 sinus tachycardia (ie, 
Symptomatic a; nonurgent medical 
interventio n indicated) with HR 120 and 
above at rest for at least 5 minutes with 
no phy sical exertion. Evaluate ECG for abnormalities, mana ge as per local guidelines and call 
the medical monitor immediately. 
In MRD, the subject may be rechallenged with the agreement of the 
sponsor and investigator. 
In MRD, if a subject develops a second episode of symptomatic 
tachycardia, discontinue treatm ent with study drug.
Any CTCAE Grade 3 sinus tachycardia 
(ie, urgent medical intervention 
indicated) or Grade 4 (life -threatening)Evaluate ECG for abnormalities, manage as per local guidelines and call 
the medical monitor immediately. 
In all subjects, discontinue further treatment with study drug.
CTCAE: Common Terminology Criteria for Adverse Events; ECG: electrocardiogram; MRD: multiple -rising dose.
a Symptoms may include dizziness, light headedness, chest pain, chest heaviness, palpitations, and sho rtness of breath.
Low Blood Pressure
If a subject develops symptoms suggestive of hypotension or postural hypotensio n, blood pressure 
shoul d be assessed for evidence of hypotension, which should be managed as per local guidelines, 
and the medical mo nitor should be contacted.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 66of 91
Protocol Incorporating Amendment No. 04 23 September 2020
Injection Site Reaction
If a subject develops a CTCAE Grade 3 (ulceration or necrosis; severe tissue damage, operative 
intervent ion need) or 4 (life -threatening consequences; urgent intervent ion indicated) discont inue 
administration of TAK -951, provi de immediate treatment and contact medical mo nitor.
Hypersensitivity
If anaphylaxis or other serious allergic react ions occur, TAK -951 administration will be 
discontinued immediately  and appropri ate m anagement init iated (eg, epinephrine, and
antihistamines, and further immediate care as necessary). 
10.2.8.5 Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST >3 times the ULN and total bilirubin >2 times the ULN, 
the event should be recorded as an SAE and reported as per Section 10.2.8.3 . The invest igator must 
contact the medical mo nitor for discussio n of the relevant subject details and possible alternat ive 
etiologies, such as acute viral hepat itis A or B or other acute live r disease. Follow -up laboratory  
tests as described in Sect ion 9.3must also be performed. 
10.2.9 Safety Reporting to Investigators, IRBs, and Regulatory Authorities 
Thesponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, invest igators, and IRBs, as 
applicable, in accordance with national regulat ions in the countries where the study  is conducted. 
Relative to the first awareness o f the event by /or further provisio n to the sponsor or sponsor’s 
designee, SUSARs will be submitted within 7 days for fatal and life -threatening events and 
15days for other seri ous events, unl ess otherwi se requi red by nat ional regulat ions. The sponsor 
will also prepare an expedited report for other safety  issues where these might materially  alter the 
current benefit -risk assessment of an invest igational medicinal product or that would be suffic ient 
to consi der changes in the invest igational medicinal products administration or in the overall 
conduct of the study . The investigational site also will forward a copy  of all expedited reports to 
his or her IRB in accordance wit h nat ional regulations.
11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized before database lock. This 
docum ent will provi de further details regarding the definit ion of analysis variables and analysis 
methodol ogy to address all study  objectives.
A targeted data review will be conducted before database lock. This review will assess the 
accuracy  and com pleteness of the study  database, subject evaluabilit y, or appropri ateness of the 
planned statistical methods.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 67 of 91Protocol Incorporating Amendment No. 04 23 September 2020
11.1.1 Analysis Sets
11.1.1.1 Safety Set
The safety analysis set will consist of all subjects who are enrolled and receive study drug. 
Subjects in this analysis set will be used for demographic, baseline characteristics, and safety 
summaries. 
11.1.1.2 PK Set
The PK analysis set will consist of all subjects who receive study drug and have at least 1 
measurable plasma concentration of TAK-951.
11.1.1.4 Immunogenicity Set
The immunogenicity set consists of patients who receive at least 1 dose of TAK-951 and have an 
ADA status assessment at baseline, and at least 1 postbaseline sample.
11.1.2 Analysis of Demography and Other Baseline Characteristics
Descriptive statistics (N, mean, standard deviation, median, minimum, and maximum) will be 
generated for continuous demographic variables and baseline characteristics variables (eg, age, 
height, weight, and BMI) for pooled placebo group, each TAK-951 dose level, TAK-951 overall in 
Part 1 and Part 3. The number and percentage of subjects in each class of the categorical 
demographic variables and baseline characteristics variables (eg, gender, ethnicity, race) will be 
tabulated for pooled placebo group, each TAK-951 dose level, and overall. Placebo data will be 
pooled across c ohorts within each part of the study. Individual subject demographic and baseline 
characteristics data will be listed.
11.1.4 PK Analysis
The plasma and urine concentrations of TAK-951 will be summarized by dose, cohort, day, and 
dosing condition (as appropriate) over each scheduled sampling time, using descriptive statistics. 
The PK parameters of TAK-951 will be determined from the concentration-time profiles for all 
evaluable subjects using noncompartmental analysis approach. Actual sampling times, rather than 
scheduled sampling times, will be involved in the derivation of PK parameters. Dose CCICCI
Property 11.111.For Non-Commercial Use Only and receivereceiv
t 1 post1 post
Other BOther
dard devard d
aphic vaphic v
ooled plaoled p
er and pr and
d baseld base
acebo gacebo 
rts withis wit
ta will a wilApplicable Terms of Usefetety y 
ave at leve at 
y of Takeda: Fod Subject to the A
TAK-951
Study ID TAK-951-1001 Page 68 of 91Protocol Incorporating Amendment No. 04 23 September 2020
proportionality will be asse ssed graphically (dose-norm alized C maxand AUC versus dose) as data 
allows; no formal statist ical comparisons w ill be conducted.
Additional PK parameters may be calculated as appropriate. Further details will be specified in the 
SAP.
11.1.5 Safety Analysis
Safety analyses will be based on the safety analysi s set. No formal statistical tests or inference will 
be performed for safety analyses. All summaries will be performed by pooled placebo within each 
part, and TAK-951 dose level.
11.1.5.1 AEs
Treatment-emergent advers e events (TEAEs) will be summarized by placebo, each TAK-951 dose 
level and TAK-951 overall for each part of the study.
11.1.5.2 Clinical Laboratory Evaluations
Baseline, postdose, and change from baseline to postdose laboratory data will be summarized by
treatment. Individual results of laboratory tests from hematology, chemistry,  and urinalysis that 
meet Takeda’s markedly abnormal criteria will be summarized. All clinical laboratory data will be 
provided in  the data listings.
11.1.5.3 Vital Signs
Vital signs data will be summarized using descriptive statistics for each cohort. Individual vital 
sign results meeting the sponsor’s markedly abnormal criteria will also be summarized.
11.1.5.4 ECG
ECG data captured through telemetry and Holter will be listed by subject and treatment group for 
each part.
11.1.5.5 Other Safety Parameters
Physical examination findings will be presented in the data listings.
11.1.7 Immunogen icity Analysis
Immunogenicity will be summarized using the Immunogenicity set. Descriptive statistics will be 
used to summarize subjects in the following cate gories: ADA negative, ADA positive, low or high 
ADA titer.CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehe e 
r infereninfer
lacebo wacebo
y placeby place
ose labose lab
hemathema
e summsumm
using deusing 
s mmarkedarke
ugh telegh te
er Safeter Saf
aminataminat io
11erty of Takeda
TAK-951
Study ID TAK-951-1001 Page 69 of 91Protocol Incorporating Amendment No. 04 23 September 2020
The relationship between immunogenicity status (ADA and ADA titer) and PK, and 
safety may be explored. Further details will be provided in the SAP.
11.2 Interim Analysis and Criteria for Early Termination
No formal interim analysis is planned. Section 6.0describes the safety, tolerability and PK review 
that will take place after completion of each cohort and before next dose escalation stage in the 
study.
11.3 Determination of Sample Size
For Parts 1 and 3, the selected sample sizes ar e considered sufficient for evaluation of safety,
tolerability, PK, and PD. The study is not s tatistically powered to pe rform hypothesis testing in 
Parts 1 and 3.
12.0 QUALITY CONTROL AND QUALITY ASSURANCE
12.1 Study-Site Monitoring Visits
Monitoring visits to the study site will be mad e periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The investigator and study site guarantee access to source documents by the sponsor or its 
designee (CRO) and by the IRB.
All aspects of the study and its documentation w ill be subject to review by the sponsor or the 
sponsor’s designee (as long as blinding is not jeopardized), including but not limited to the 
investigator’s binder, study drug, subj ect med ical records, informed consent documentation, and 
review of eCRFs and associated source documents. It is important that the investigator and other 
study personnel are available during the monitoring visits and that sufficient time is devoted to the 
process.
12.2 Protocol Deviations
The investigator should not deviate from the prot ocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviation from protocol-specified procedures, the investigator should consult with the sponsor or 
designee (and IRB, as required) to determine the appropriate course of action. There will be no 
exemptions (a prospectively approved deviation)  from the inclusion or exclusion criteria.
Significant deviations include, but are not limited to, those that involve fraud or misconduct, 
increase the health risk to the subject, or confound interpretation of primary study assessment. 
12.3 Quality Assurance Audits and Regulatory Agency Inspections
The study site also may be subject to quality assura nce audits by the sponsor or designees. In this 
circumstance, the sponsor-designated auditor w ill contact the site in a dvance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseK reviewrevie
ge in the in t
valuataluat ioio
rm hyporm hyp
NCECE
dicallycally dy
ments wients w
defined defined
cess to ss to 
entatintation
ding is ning is
g, subjsubjec
ted sourd sou
ble durinble du
DeviatDevia
tor shouor sho
hazard hazard
n nfrofrom m
nee (annee (an
emptmpioi
SiSignifgn
incin
TAK -951
Study ID TAK -951-1001 Page 70of 91
Protocol Incorporating Amendment No. 04 23 September 2020
where the medication is stored and prepared, and any other facilit y used during th e study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
Products Regulatory  Agency , the Pharmaceut icals and Med ical Devices Agency  of Japan). If the 
study  site is contacted for an inspect ion by a regulatory  body , the sponsor should be notified 
immediately . The investi gator guarantees access for qualit y assurance auditors to all study  
docum ents as described in Sect ion 12.1.
13.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protoco l, the ethical principles that have their origin in the Declarat ion of Helsinki, 
and the ICH Harmonised Tripartite Guideline for GCP. Each invest igator will conduct the study 
according to applicable local or regional regulatory requirements and align his o r her conduct in 
accordance with the “Responsibilit ies of the Investigator” that are listed in Appendix A. The 
principles of Helsinki are addressed through the protoco l and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
13.1 IRB Approval
IRBs m ust be consti tuted according to the applicable state and federal/local requirements of each 
participat ing region. The sponsor or des ignee will require documentation noting all names and 
titles of members who make up the IRB. If any member of the IRB has direct participat ion in this 
study , written notificat ion regarding his or her abstinence fro m voting must al so be obtained. 
Those Amer icas sites unwilling to provide names and tit les of all members due to privacy  and 
conflict of interest concerns should instead provide a Federal Wide Assurance Number or 
comparable number assigned by  the Department of Heal th and Human Services.
The sponso r or desi gnee will  supply relevant documents for submission to the IRB for the 
protocol ’s review and approval. This protocol, the Investigator’s Brochure, a copy of the informed 
consent form, and, if applicable, subject recruitment materials and/or adverti sements and other 
docum ents requi red by all applicable l aws and regul ations, m ust be submitted to a central or local 
IRB for approval. The IRB’s written approval of the protocol and subject informed consent must 
be obtained and submitted to the sponsor or designee before commencement of the study (ie, 
before shipment of the sponsor -supplied drug or study specific screening act ivity). The IRB 
approval  must refer to the study by exact protocol title, number, and versio n date; ident ify versio ns 
of other docume nts (eg, informed consent form) reviewed; and state the approval date. The 
sponsor will ship drug/notify site once the sponsor has confirmed the adequacy  of site regul atory  
docum entati on and, when applicable, the sponsor has received permissio n from compet ent 
authori ty to begin the study . Unt il the site receives drug/notificat ion no protocol activit ies, 
including screening, may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB. This may include 
notification to the IRB regarding protocol  amendments, updates to the informed consent form, 
recrui tment m aterials intended for viewing by  subjects, l ocal safet y reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the IRB, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 71of 91
Protocol Incorporating Amendment No. 04 23 September 2020
and su bmissio n of the invest igator’s final status report to IRB. All IRB approvals and relevant 
docum entati on for these i tems m ust be provi ded to the sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subj ects m ust 
be approved by the IRB and sponsor.
13.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benef its, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB approval o f the inform ed 
consent form and, if applicable, the subject authorization form. The informed consent form, 
subject authorizat ion form (if applicable), and subject i nform ation sheet (if applicable) must be 
approved by  the IRB and the sponsor before use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information s hould be given in both oral and written form whenever possible and in the 
manner deemed appropriate by  the IRB. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representative may
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details o f the study, and (2) decide whether ornot to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and dated by the subject, or the subject’s legally acceptable representative, at the time of 
consent and before the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not ni cknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and before the subject enters 
into the study; however, the sponsor may  allow a designee of the invest igator to sign to the extent 
permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s si te file. The 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 72of 91
Protocol Incorporating Amendment No. 04 23 September 2020
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date t he revised consent was obtained should be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
Subjects who consented and provided a PGx sample for DNA and RNA analysis can withdraw 
their consent and request disposal o f a stored sample at any time before analysis. Notify sponsor of 
consent withdrawal.
13.3 Subject Confidentiality
The sponsor and designee s affirm  and uphol d the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a unique ident ificat ion num ber. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs to review the subject’s original medical records (source data or documents), 
including, but not limited to, laboratory  test resul t reports, ECG reports , admissio n and di scharge 
summaries for hospital admissions occurring during a subject’s study  parti cipat ion, and autopsy  
reports. Access to a subject’s original medical records requires the specific authorization o f the 
subject as part of the informed con sent process (see Section 13.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable in formation rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
13.4 Publication, Disclosure, and Clinical Study Registration Policy
13.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole resp onsibili ty of the sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 73of 91
Protocol Incorporating Amendment No. 04 23 September 2020
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropri ately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protoco l and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Trial Registration 
To ensure that informat ion on clinical studies reaches the public in a timely manner and to comply 
with applicable l aws, regul ations and g uidance, Takeda will, at a minimum register all 
intervent ional clinical studies it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact in formation, along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by  
provi ding the invest igator name, address, and phone number to the callers request ing study  
inform ation. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the study . The invest igative sites are e ncouraged to handle the study  
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of study  enro llment, th ey shoul d be referred to the sponsor.
Any invest igator who objects to the spon sor providing this informat ion to callers must provide the 
sponsor with a written notice request ing that their informat ion not be listed on the registry  site.
13.4.3 Clinical Study Results Disclosure 
Takeda will post the results of clinical studies on ClinicalTr ials.gov or other publicly  accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
13.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact the sponsor 
or sponsor’s designee.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 74of 91
Protocol Incorporating Amendment No. 04 23 September 2020
14.0 ADMINISTRATIVE AND REFERENCE INFORMATION
14.1 Administrative Information
14.1.1 Study Contact Information 
Study  contact numbers can be found in the study manual, the communication plan, or other similar 
docum ents provi ded to the si te.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 75of 91
Protocol Incorporating Amendment No. 04 23 September 2020
14.1.2 INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Broch ure, package 
insert and any  other product information provided by  the sponsor. I agree to conduct this study  in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study  subjects in accordanc e with the f ollowing:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 GCP: Consolidated Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting SAEs defined in Section 10.2.9 of this protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator ( Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 76of 91
Protocol Incorporating Amendment No. 04 23 September 2020
14.1.3 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Study -Related Responsibilit ies template. The vendors i dentified for specific study -related 
activit ies will perf orm these act ivities in full or in partnership wi th the sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 77 of 91Protocol Incorporating Amendment No. 04 23 September 2020
14.1.4 List of Abbreviations
ADA anti-drug antibody
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC∞ area under the concentration-time curve from time 0 to infinity, calculated using the 
observed value of the last quantifiable concentration
AUCτ area under the concentration-time curve during a dosing interval
AV atrioventricularBMI body mass index
BPM beats per minute
CL/F
apparent clearance after extravascular administration
Cmax maximum observed concentration
CRO contract research organization
CTX carbox y-terminal collagen crosslinks
EC 50 half-maximal effective concentration
eCRF electronic case report form
ECG electrocardiogram
FDA Food and Drug AdministrationFIH first-in-human
FSH follicle stimulating hormone
GCP Good Clinical Practice
GLP Good Laboratory Practice
GLP-1 glucagon like 
peptide-1
hCG human chorionic gonadotropin
HED human equivalent dose
HR heart rate
ICH International Conference on Harmonisation
IRB institutional review board
IV intravenousLFT liver function test
MedDRA Medical Dictionary for Regulatory Activities
MRD multiple-rising dose
NOAEL no observed adverse effect level
NOEL no observed effect level
NRS Numeric Rating SystemCCI
CCICCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Uselated usinted us
al
istrationstratio
nkss
centratioentrati
ormrm
AdministAdmin
an
timulatinmulati
ClinicalClinic
Good LGoo
glug
V
LFTLFT
MM-Conly
TAK-951
Study ID TAK-951-1001 Page 78 of 91Protocol Incorporating Amendment No. 04 23 September 2020
PK pharmacokinetic
QTcF QT interval with Fridericia correction method
RBC red blood cell
SAE serious adverse event
SAP statistical analysis planSC subcutaneous
SD single dose
SRD single-rising dose
SUSAR suspected unexpected serious adverse reactions
TAG triacylglyceride
TEAE treatment-emergent adverse event
T
1/2z terminal disposition phase hal f-life
ULN upper limit of normal
Vz/F apparent volume of distribution during the terminal phase after extravascular 
administration
WBC white blood cellCCICCCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useduring thuring t
TAK -951
Study ID TAK -951-1001 Page 79of 91
Protocol Incorporating Amendment No. 04 23 September 2020
15.0 DATA HANDLING AND RECORDK EEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, m edical history , and concurrent conditions will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Drugs will be coded using the World Healt h Organizat ion Drug 
Dictionary.
15.1 CRFs (Electronic and Paper)
Com pleted eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply investigative sites with access to eCRFs. T he sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the sponsor and regulatory  
authori ties. eCRFs must be completed in Engl ish. Data are transcribed direct ly onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or desi gnees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be included. 
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the eCRFs should be made by the investigator with use of change and modificat ion records of 
the eCRFs. The principal investigator must review the data change for completeness and accuracy, 
and must sign and date . 
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or its designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available i n any form  to thi rd parti es, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
15.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medi cal records, tem porary  media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms ), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 80 of 91Protocol Incorporating Amendment No. 04 23 September 2020
enable evaluations or audits from regulatory au thorities, the sponsor or its designees. Any source 
documentation printed on degradable thermal sensitive paper should be photocopied by the site 
and filed with the original in the subject’s chart to ensure long-term legibility. Furthermore, ICH 
E6 Section 4.9.5 requires the investigator to re tain essential documents specified in ICH E6 
(Section 8) until at least 2 years after the last appr oval of a marketing application for a specified 
drug indication being investigated or, if an application is not approved, until at least 2 years after 
the investigation is discontinued and regulatory authorities are notified. In addition, ICH E6 
Section 4.9.5 states that the study records should be retained until an amount of time specified by
applicable regulatory requirements or for a time specified in the Clinical Study Site Agreement 
between the investigator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator and the head of the institution should contact and receive written approval from the 
sponsor before disposing of any such documents.
16.0 REFERENCESCCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseH 
cified ified 
years aftears a
ICHCHE6E
me specme spe
ySiSite Agte Aiii
ts on recon r
e writtenwritt
roperty of Takeda: For Non-Commercial Use Only and Subje
TAK -951
Study ID TAK -951-1001 Page 81of 91
Protocol Incorporating Amendment No. 04 23 September 2020
17.0 APPENDICES
Appendix AResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform
study -related duti es and funct ions, the invest igator/inst itution shoul d ensure that this
individual or party  is qualified to perform those study -related duti es and functi ons and shoul d
implement procedures to ensure the integrity  of the study -related duti es and funct ions
perform ed and any  data generated.
4.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel)
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written
approval  from relevant governing bodies/authorit ies.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of
these obligat ions.
6.Secure prior approval of the study  and any  changes by  an appropri ate IRB that conform to 21
CFR Part 56, ICH, and local regulatory  requi rements.
7.Ensure th at the IRB will be responsible for init ial review, continuing review, and approval of
the protocol. Promptly report to the IRB all changes in research activit y and all ant icipated
risks to subjects. Make at least yearly reports on the progress of the study to the IRB, and issue
a final report within 3 months of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local
regul ations, are m et.
9.Obtain valid informed consent from each subject who participates in the study , and docum ent
the date of consent in the subject’s medical chart. Valid informed consent is the most current
versio n approved by the IRB. Each informed consent form should contain a subject
authori zation sect ion that describes the uses and discl osures of a subject’s personal
inform ation (including personal health informat ion) that will take place in connect ion wit h the
study . If an informed consent form does not include such a subject authorization, then the
investigator must obtain a separate su bject authorization form from each subject or the
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding
eCRFs, hospital records, laboratory  resul ts, etc, and maintain thes e data for a minimum o f
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 82of 91
Protocol Incorporating Amendment No. 04 23 September 2020
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor. 
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 83of 91
Protocol Incorporating Amendment No. 04 23 September 2020
Appendix BElements of the Subject Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of th e procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or disco mforts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to w hich confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regulatory  agencies, audi tor(s), IRB, and 
the monitor m ay inspect the records. By  signing a wri tten inform ed consent form , the subject 
or the subject’s legally  acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any medical treatments are available if injury occurs and, if so, 
what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB and who m to contact in the event of a research -related 
injury  to the subject.
19.A statement that participation is vo luntary, that r efusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the subject otherwise is ent itled, and that the subject or the subject’s 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 84of 91
Protocol Incorporating Amendment No. 04 23 September 2020
legally acceptable representative may discont inue participat ion at any  time wi thout penal ty or 
loss of benef its to whi ch the subject is otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the study .
22.A statement that results of PGx analysis will not be disclo sed to an individual, u nless 
prevailing laws require the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contained within the informed consent form or provi ded 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other h ealth authori ties; and (4) IRBs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the da ta protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal heal th informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease, a nd improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 85of 91
Protocol Incorporating Amendment No. 04 23 September 2020
25.Male subjects must use highly effect ive contraceptio n (as defined i n the informed consent) 
from signing the informed consent throughout the duration of the study  and f or 5 half -lives 
after the l ast dose of study  drug. If the partner or wife of the subject is found to be pregnant 
during the study , the invest igator will o ffer the subject the choice to receive unblinded 
treatm ent information. 
26.A statement that clinical study  informat ion from this study  will be publicly disclo sed in a 
publicly  accessible website, such as ClinicalTrials.gov.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 86of 91
Protocol Incorporating Amendment No. 04 23 September 2020
Appendix CInvestigator Consent to the Use of Personal Information 
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
information may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affil iates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessme nt of the sui tabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the s tudy.
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal infor mation may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal infor mation by Takeda 
and other parties for the purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 87of 91
Protocol Incorporating Amendment No. 04 23 September 2020
Appendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Male Subjects and Their Female Partners
From  signing of informed consent, throughout the duration of the study , and for 5 half -lives after 
last dose of study  drug, nonsterilized** male subjects who are sexually  active wi th a female 
partner of childbearing potential* must use barrier contraceptio n (eg, condom  with or wi thout 
spermicidal cream or jelly). In addit ion, they  must be advised not to donate sperm during this 
period. Females of childbearing potential who are partners of male subjects are also advised to use 
additional contracepti on as sho wn in the list containing highly effect ive/effect ive contraception 
below.
Definitions and Procedures for Contraception and Pregnancy Avoidance
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
* A wom an is considered a w oman of childbearing potential, ie, fert ile, fo llowing menarche and 
until becoming postmenopausal unless permanent ly sterile. Permanent sterilizat ion methods 
include hysterectomy, and bilateral oophorectomy . A postmenopausal state is defined as no 
menses f or 12 m onths wi thout an al ternative m edical  cause. A high FSH level in the 
postm enopausal  range (FSH >40 IU/L) may be used to confirm a postmenopausal state in younger 
wom en (eg, those <45 years old) or women who are not using hormonal contraception or hor monal 
replacement therapy . However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient.
** Sterilized males should be at least 1 year post -bilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchi dectomy .
The follow ing procedures apply for contraception and pregnancy avoidance.
1.Highly effect ive methods of contraception are defined as “those, alone or in combinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
correctly ). In this study , where m edicat ions and devices containing hormones are 
included/excluded, the only acceptable methods of contraception are: 
Non-Hormonal Methods: 
–IUD (Intrauterine device).
–Bilateral tubal occlusio n.
–Vasectomised partner (provided that partner is the sole sexual partner of the study  
participant and that the vasectomised partner has received medical assessment of the 
surgi cal success.
–True sexual abstin ence, only  if this is in line wit h the preferred and usual lifest yle of the 
subject. True abst inence is defined as refraining from heterosexual intercourse during the 
entire peri od of  the study , from 1 month pri or to the first dose until 5 half- lives.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 88of 91
Protocol Incorporating Amendment No. 04 23 September 2020
Horm onal Methods: Horm onal contracepti on m ay be suscept ible to interaction with the 
investigat ive co mpound, comparator, concomitant medicat ions, which may reduce the efficacy 
of the contracepti on m ethod (evaluate on compound -by-compound and protocol -by-protoco l 
basis and obtain clinical pharmaco logy justificat ion).
–Combined (estrogen and progestogen) hormonal contraception associated with inhibit ion 
of ovul ation initiated at least 3 months prior to the first dose of study  drug OR combined 
with a barrier method (male condo m, female condom or diaphragm) if for shorter duration 
until she has been on contraceptive for 3 months;
Oral †.
Intravaginal † (eg, ring).
transderm al †.
–Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation1 
initiated at least 3 m onths pri or to the first dose of study  drug OR combined with a barrier 
method (male condo m, female condom or diaphragm) if for shorter duration unt il she has 
been on contraceptive for 3 months;
oral †.
Injectable.
Implantable.
2.If genotoxicit y/teratogenicit y/embry otoxi city is unlikely  to be caused by  the investi gational 
drug, com parator, background therapy  or standard of care medicationseffect ive methods of 
contraception (there may  be a hi gher than 1% failure rate) are: 
Doubl e-barrier method ( contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellies or creams PLUS male condo m).
Progestogen only  hormonal contracepti on, where inhibit ion of ovulat ion is not the primary 
mode of act ion PLUS condom wit h or without spermicide.
3.Unaccepta ble methods of contraception are:
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, postovulat ion methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
Sexual abst inence is NOT an acceptable method of contraception.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -951
Study ID TAK -951-1001 Page 89of 91
Protocol Incorporating Amendment No. 04 23 September 2020
4.Subjects will be provided with information on highly effect ive/effect ive methods of 
contraception as part of the subject informed consent process and will be asked to sign a 
consen t form stating that they  understand the requirements for avoidance of pregnancy, 
donati on of  ova, and sperm donat ion during the course of the study .
5.During the study , regul ar serum /urine human chorioni c gonadotropin (hCG) pregnancy tests 
will be performed for female subjects and all subjects (male and female) will receive continued 
guidance wi th respect to the avoidance of pregnancy  and sperm  donat ion as part of the study  
procedures. Such guidance should include a reminder of the fo llowing:
contraceptive re quirements of the study
reasons for use of barrier methods (ie, condom) in males with pregnant partners
assessment of subject compliance through questions such as
–Have you used the contraception consistent ly and correctly since the last visit ?
– H ave y ou forgotten to use contraception since the last visit ?
–Are y our menses l ate? (even in wom en wi th irregular or infrequent menstrual cycles a 
pregnancy test must be performed if the answer is “yes”)
–Is there a chance you could be pregnant ?
Pregnancy
Women of childbearing potential will not be included in this study .
If any subject is found to be pregnant during the study  she shoul d be wi thdrawn and any 
sponsor -supplied drug should be immediately discontinued. 
Shoul d the pregnancy  occur during or after adminis tration of  blinded drug, the invest igator must 
inform  the subject of their right to receive treatment information. If the subject chooses to receive 
unblinded treatment informat ion, the individual blind should be broken by the invest igator. 
If the female subject and/or female partner of a male subject agrees to the primary care physician 
being informed, the invest igator should notify the primary care physician that the female 
subject/female partner of the subject was participating in a clinical study  at th e time she became 
pregnant and provide details o f the study  drug the subject received (blinded or unblinded, as 
applicable).
All pregnancies, including female partners of male subjects, in subjects on active study  drug 
(including co mparator, if applicable) will be fo llowed up to final outcome, using the pregnancy  
form. Pregnancies will remain blinded to the study team. The outcome, including any  premature 
termination, must be reported to the sponsor. An evaluat ion after the birth o f the child will also be 
conducted.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-951
Study ID TAK-951-1001 Page 90 of 91Protocol Incorporating Amendment No. 04 23 September 2020
Appendix E Detailed Description of Amendments to Text
This document describes changes in reference to Protocol Incorporating Amendment No. 04.
Rationale for Chan ge: All references to Part 2 of the study have been removed 
The following sections contain these changes:
!Section 1.0 STUDY SUMMARY
!Section 2.0 STUDY SCHEMATIC
!Section 3.2Part 2 for SD Apo Cohorts 7 to 9 (section content has been deleted)
!Section 4.2 Rationale for the Proposed Study
!Section 4.3 Benefit-Risk Profile
!Section 5.1 Study Objectives
!Section 5.2 Endpoints
!Section 6.1 Study Design,  including references to Part 2 in Table 6.a
!Section 6.1.2
!Section 6.2.1 Rati onale of Study Design
!Section 6.2.2.
!Section 6.2.2.3
!Section 6.2.4 Rationale for EndpointsCCI
CCI
CCI
CCICCI
Property of Takeda: For Non-Commercial Uchangechang
ARYARY
HEMATEMA
or SD Ar SD 
onale foonale 
BenefitBenef
5.15.1StuS
ctiionon5.25
SectiSecti o
!!S
!l Use Onart 2 of tt 2 ofof Useo
lUOnly and Subject to the Applicable Terms o
TAK-951
Study ID TAK-951-1001 Page 91 of 91Protocol Incorporating Amendment No. 04 23 September 2020
!Section 6.2.5 Critical P rocedures Based on Study Objectives: Timing of Procedures
!Section 6.3 Study Design/Dosing/Procedures Modi fications Pe rmitted Within Protocol 
Parameters
!Section 6.4.5 Stoppi ng Rules
!Section 7.2 Exclusion Criteria and Section 1.0 STUDY SUMMARY Main Criteria for 
Exclusion
!Section 7.4.1.2 Part 2 (under Diet and Fluid)
!Section 8.1.1.2
!Section 8.1.1.3 
!Section 8.1.2 Use of Rescue Medication (section has been deleted)
!Section 8.1.3 Clin ical Study Drug Inventory and Storage
!Section 8.1.7 Acc ountability and Destruction of Sponsor-Supplied Drugs
!Section 8.3 Companion Medication (section has been deleted)
!Section 8.4 Rescue Medication (section has been deleted)
!Section 9.2.4 Vital Signs
!Section 9.2.5 Glucose
!Section 9.2.6.2 Telemetry
!Section 9.2.7 Study Drug Administration
!!!Section 9.5.2 Part 2 (SD Apo Challenge)
!Section 11.1.1.3 PD Set
!Section 11.1.2 Analysis of Demography and Other Baseline Characteristics
!!!Section 11.3 Determination of Sample SizeCCICCICCI
CCI
CCI
CCI
Property of Takeda: For NoPart 2 (Sart 2 
.1.1.31.1 P
onn11.1.11.1Commercial Use Only and Subject to the Applicable Terms of Usea ffor rff
leted)eted)
nsornsor--SuSu
been deeen d
been deeen d
Adminisdmini
!!Non-CCom
fT a k e
y of TCCICC
(/(&7521,& 6,*1$785(6
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GHII䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢶䢢䣶䣱䢢䣃䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣆䣱䣷䣤䣮䣧䢯䣄䣮䣫䣰䣦䢮䢢䣒䣮䣣䣥䣧䣤䣱䢯䣅䣱䣰䣶䣴䣱䣮䣮䣧䣦䢮䢢 䣖䣪䣴䣧䣧䢯䣒䣣䣴䣶䢢䣒䣪䣣䣵䣧䢢䢳䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧
䣕䣣䣨䣧䣶䣻䢮䢢䣖䣱䣮䣧䣴䣣䣤䣫䣮䣫䣶䣻䢮䢢䣣䣰䣦䢢䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢢䣱䣨䢢䣖䣃䣍䢢䢻䢷䢳䢢䣫䣰䢢䣊䣧䣣䣮䣶䣪 䣻䢢䣕䣷䣤䣬䣧䣥䣶䣵䢰
3KDUPDFRYLJLODQFH$SSURYDO 6HS87&
%LRVWDWLVWLFV$SSURYDO 6HS87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO 6HS87&
&OLQLFDO$SSURYDO 6HS87&PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeT eate te
ble THH:mm ‘UH:mmTer
ble87&87&

6HSHS
6H